Document:

Nuvelo, Inc. 2004 Equity Incentive Plan

 Exhibit 10.34 
 NUVELO, INC. 
 2004 EQUITY INCENTIVE PLAN 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	 1.
	  	Establishment, Purpose and Term of Plan	  	A-1
		  	1.1 Establishment	  	A-1
		  	1.2 Purpose	  	A-1
		  	1.3 Term of Plan	  	A-1
	 2.
	  	Definitions and Construction	  	A-1
		  	2.1 Definitions	  	A-1
		  	2.2 Construction	  	A-5
	 3.
	  	Administration	  	A-5
		  	3.1 Administration by the Committee	  	A-5
		  	3.2 Authority of Officers	  	A-5
		  	3.3 Administration with Respect to Insiders	  	A-5
		  	3.4 Committee Complying with Section 162(m)	  	A-5
		  	3.5 Powers of the Committee	  	A-5
		  	3.6 No Repricing	  	A-6
		  	3.7 No Restricted Stock Award Acceleration	  	A-6
		  	3.8 Indemnification	  	A-6
	 4.
	  	Shares Subject to Plan	  	A-7
		  	4.1 Maximum Number of Shares Issuable	  	A-7
		  	4.2 Adjustments for Changes in Capital Structure	  	A-7
	 5.
	  	Eligibility and Award Limitations	  	A-7
		  	5.1 Persons Eligible for Awards	  	A-7
		  	5.2 Participation	  	A-8
		  	5.3 Incentive Stock Option Limitations	  	A-8
		  	5.4 Award Limits	  	A-8
	 6.
	  	Terms and Conditions of Options	  	A-9
		  	6.1 Exercise Price	  	A-9
		  	6.2 Exercisability and Term of Options	  	A-9
		  	6.3 Payment of Exercise Price	  	A-9
		  	6.4 Effect of Termination of Service	  	A-10
		  	6.5 Transferability of Options	  	A-10
	 7.
	  	Terms and Conditions of Stock Appreciation Rights	  	A-10
		  	7.1 Types of SARs Authorized	  	A-10
		  	7.2 Exercise Price	  	A-10
		  	7.3 Exercisability and Term of SARs	  	A-11
		  	7.4 Exercise of SARs	  	A-11
		  	7.5 Deemed Exercise of SARs	  	A-11
		  	7.6 Effect of Termination of Service	  	A-11
		  	7.7 Nontransferability of SARs	  	A-11
	 8.
	  	Terms and Conditions of Restricted Stock Awards	  	A-12
		  	8.1 Types of Restricted Stock Awards Authorized	  	A-12
		  	8.2 Purchase Price	  	A-12
		  	8.3 Purchase Period	  	A-12
		  	8.4 Payment of Purchase Price	  	A-12
		  	8.5 Vesting and Restrictions on Transfer	  	A-12
		  	8.6 Voting Rights; Dividends and Distributions	  	A-12
		  	8.7 Effect of Termination of Service	  	A-13
		  	8.8 Nontransferability of Restricted Stock Award Rights	  	A-13

  

 A-i 

					
	 	  	 	  	Page
	 9.
	  	Terms and Conditions of Performance Awards	  	A-13
		  	9.1 Types of Performance Awards Authorized	  	A-13
		  	9.2 Initial Value of Performance Shares and Performance Units	  	A-13
		  	9.3 Establishment of Performance Period, Performance Goals and Performance Award Formula	  	A-13
		  	9.4 Measurement of Performance Goals	  	A-14
		  	9.5 Settlement of Performance Awards	  	A-15
		  	9.6 Voting Rights; Dividend Equivalent Rights and Distributions	  	A-16
		  	9.7 Effect of Termination of Service	  	A-16
		  	9.8 Nontransferability of Performance Awards	  	A-16
	 10.
	  	Terms and Conditions of Restricted Stock Unit Awards	  	A-16
		  	10.1 Grant of Restricted Stock Unit Awards	  	A-16
		  	10.2 Purchase Price	  	A-16
		  	10.3 Vesting	  	A-17
		  	10.4 Voting Rights, Dividend Equivalent Rights and Distributions	  	A-17
		  	10.5 Effect of Termination of Service	  	A-17
		  	10.6 Settlement of Restricted Stock Unit Awards	  	A-17
		  	10.7 Nontransferability of Restricted Stock Unit Awards	  	A-17
	 11.
	  	Deferred Stock Units	  	A-18
		  	11.1 Establishment of Deferred Stock Unit Program	  	A-18
		  	11.2 Terms and Conditions of Deferred Stock Units	  	A-18
	 12.
	  	Standard Forms of Award Agreement	  	A-19
		  	12.1 Award Agreements	  	A-19
		  	12.2 Authority to Vary Terms	  	A-19
	 13.
	  	Change in Control	  	A-19
		  	13.1 Definitions	  	A-19
		  	13.2 Effect of Change in Control on Options and SARs	  	A-20
		  	13.3 Effect of Change in Control on Restricted Stock Awards	  	A-20
		  	13.4 Effect of Change in Control on Performance Awards	  	A-21
		  	13.5 Effect of Change in Control on Restricted Stock Unit Awards	  	A-21
		  	13.6 Effect of Change in Control on Deferred Stock Units	  	A-21
	 14.
	  	Compliance with Securities Law	  	A-21
	 15.
	  	Tax Withholding	  	A-21
		  	15.1 Tax Withholding in General	  	A-21
		  	15.2 Withholding in Shares	  	A-21
	 16.
	  	Amendment or Termination of Plan	  	A-22
	 17.
	  	Miscellaneous Provisions	  	A-22
		  	17.1 Repurchase Rights	  	A-22
		  	17.2 Provision of Information	  	A-22
		  	17.3 Rights as Employee, Consultant or Director	  	A-22
		  	17.4 Rights as a Stockholder	  	A-22
		  	17.5 Fractional Shares	  	A-22
		  	17.6 Severability	  	A-22
		  	17.7 Beneficiary Designation	  	A-23
		  	17.8 Unfunded Obligation	  	A-23

  

 A-ii 

 AMENDED AND RESTATED 
 NUVELO, INC. 
 2004 EQUITY INCENTIVE PLAN 
  

	1.	ESTABLISHMENT, PURPOSE AND TERM OF PLAN. 

 1.1 Establishment. The Nuvelo, Inc. 2004 Equity Incentive Plan (the “Plan”) was originally
established effective as of May 6, 2004, the date of its approval by the stockholders of the Company (the “Effective Date”), and was subsequently amended and restated on May 24, 2005. The Plan was again,
subject to stockholder approval, amended and restated by the Board on March 7, 2006, and was approved by the stockholders on May 24, 2006. 
 1.2 Purpose. The purpose of the Plan is to advance the interests of the Participating Company Group and its stockholders by providing an incentive to attract, retain and reward persons
performing services for the Participating Company Group and by motivating such persons to contribute to the growth and profitability of the Participating Company Group. The Plan seeks to achieve this purpose by providing for Awards in the form of
Options, Indexed Options, Stock Appreciation Rights, Restricted Stock Purchase Rights, Restricted Stock Bonuses, Performance Shares, Performance Units, Restricted Stock Units and Deferred Stock Units. After the Effective Date, the Company shall
terminate, and no longer issue any awards from under, the Company’s 2002 Equity Incentive Plan, Director Stock Option Plan, Scientific Advisory Board/Consultants Stock Option Plan, 1995 Stock Option Plan and the Variagenics 1997 Employee,
Director & Consultant Stock Option Plan. 
 1.3 Term of Plan. The Plan shall continue in effect until the earlier of its
termination by the Board or the date on which all of the shares of Stock available for issuance under the Plan have been issued and all restrictions on such shares under the terms of the Plan and the agreements evidencing Awards granted under the
Plan have lapsed. However, all Incentive Stock Options shall be granted, if at all, within ten (10) years from the Effective Date. 
  

	2.	DEFINITIONS AND CONSTRUCTION. 

 2.1 Definitions. Whenever used herein, the following terms shall have their respective meanings set forth below: 
 (a) “Affiliate” means (i) an entity, other than a Parent Corporation, that directly, or indirectly through one or more intermediary entities, controls the Company or
(ii) an entity, other than a Subsidiary Corporation, that is controlled by the Company directly, or indirectly through one or more intermediary entities. For this purpose, the term “control” (including the term “controlled
by”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of the relevant entity, whether through the ownership of voting securities, by contract or otherwise; or shall have such
other meaning assigned such term for the purposes of registration on Form S-8 under the Securities Act. 
 (b)
“Award” means any Option, Indexed Option, SAR, Restricted Stock Purchase Right, Restricted Stock Bonus, Performance Share, Performance Unit, Restricted Stock Unit or Deferred Stock Unit granted under the Plan.

 (c) “Award Agreement” means a written agreement between the Company and a Participant setting forth
the terms, conditions and restrictions of the Award granted to the Participant. An Award Agreement may be an “Option Agreement,” an “Indexed Option Agreement,” a “SAR Agreement,” a “Restricted Stock Purchase
Agreement,” a “Restricted Stock Bonus Agreement,” a “Performance Share Agreement,” a “Performance Unit Agreement,” a “Restricted Stock Unit Agreement,” or a “Deferred Stock Unit Agreement.”

 (d) “Board” means the Board of Directors of the Company. 
 (e) “Code” means the Internal Revenue Code of 1986, as amended, and any applicable regulations promulgated
thereunder. 
  

 A-1 

 (f) “Committee” means the Compensation Committee or other committee
of the Board duly appointed to administer the Plan and having such powers as shall be specified by the Board. If no committee of the Board has been appointed to administer the Plan, the Board shall exercise all of the powers of the Committee granted
herein, and, in any event, the Board may in its discretion exercise any or all of such powers. 
 (g)
“Company” means Nuvelo, Inc., a Nevada corporation, or any successor corporation thereto. 
 (h)
“Consultant” means a person engaged to provide consulting or advisory services (other than as an Employee or a member of the Board) to a Participating Company, provided that the identity of such person, the
nature of such services or the entity to which such services are provided would not preclude the Company from offering or selling securities to such person pursuant to the Plan in reliance on a Form S-8 Registration Statement under the
Securities Act. 
 (i) “Deferred Stock Unit” means a bookkeeping entry representing a right granted to
a Participant pursuant to Section 11 of the Plan to receive a share of Stock on a date determined in accordance with the provisions of Section 11 and the Participant’s Award Agreement. 
 (j) “Director” means a member of the Board. 
 (k) “Disability” means the permanent and total disability of the Participant, within the meaning of
Section 22(e)(3) of the Code. 
 (l) “Dividend Equivalent” means a credit, made at the discretion
of the Committee or as otherwise provided by the Plan, to the account of a Participant in an amount equal to the cash dividends paid on one share of Stock for each share of Stock represented by an Award held by such Participant. 
 (m) “Employee” means any person treated as an employee (including an Officer or a Director who is also treated as
an employee) in the records of a Participating Company and, with respect to any Incentive Stock Option granted to such person, who is an employee for purposes of Section 422 of the Code; provided, however, that neither service as a Director nor
payment of a Director’s fee shall be sufficient to constitute employment for purposes of the Plan. The Company shall determine in good faith and in the exercise of its discretion whether an individual has become or has ceased to be an Employee
and the effective date of such individual’s employment or termination of employment, as the case may be. For purposes of an individual’s rights, if any, under the Plan as of the time of the Company’s determination, all such
determinations by the Company shall be final, binding and conclusive, notwithstanding that the Company or any court of law or governmental agency subsequently makes a contrary determination. 
 (n) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 (o) “Fair Market Value” means, as of any date, the value of a share of Stock or other property as determined by the
Committee, in its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein, subject to the following: 
 (i) If, on such date, the Stock is listed on a national or regional securities exchange or market system, the Fair Market Value of a share of Stock shall, unless expressly determined otherwise by the Committee, in its
discretion, be the average of the high and low price of a share of Stock on such date, as quoted on the Nasdaq National Market, The Nasdaq SmallCap Market or such other national or regional securities exchange or market system constituting the
primary market for the Stock, as reported in The Wall Street Journal or such other source as the Company deems reliable. If the relevant date does not fall on a day on which the Stock has traded on such securities exchange or market system,
the date on which the Fair Market Value shall be established shall be the last day on which the Stock was so traded prior to the relevant date, or such other appropriate day as shall be determined by the Committee, in its discretion. 
 (ii) If, on such date, the Stock is not listed on a national or regional securities exchange or market system, the Fair Market Value of a share of Stock
shall be as determined by the Committee in good faith without regard to any restriction other than a restriction which, by its terms, will never lapse. 
  

 A-2 

 (p) “Incentive Stock Option” means an Option intended to be (as set
forth in the Award Agreement) and which qualifies as an incentive stock option within the meaning of Section 422(b) of the Code. 
 (q)
“Indexed Option” means an Option with an exercise price which either increases by a fixed percentage over time or changes by reference to a published index, as determined by the Committee and set forth in the
Option Agreement. 
 (r) “Insider” means an Officer, a Director or any other person whose transactions
in Stock are subject to Section 16 of the Exchange Act. 
 (s) “Nonstatutory Stock Option” means
an Option not intended to be (as set forth in the Award Agreement) an incentive stock option within the meaning of Section 422(b) of the Code. 
 (t) “Officer” means any person designated by the Board as an officer of the Company. 
 (u)
“Option” means the right to purchase Stock at a stated price for a specified period of time granted to a Participant pursuant to Section 6 of the Plan. An Option may be either an Incentive Stock Option, a
Nonstatutory Stock Option or an Indexed Option. 
 (v) “Parent Corporation” means any present or future
“parent corporation” of the Company, as defined in Section 424(e) of the Code. 
 (w)
“Participant” means any eligible person who has been granted one or more Awards. 
 (x)
“Participating Company” means the Company or any Parent Corporation, Subsidiary Corporation or Affiliate. 
 (y) “Participating Company Group” means, at any point in time, all entities collectively which are then Participating Companies. 
 (z) “Performance Award” means an Award of Performance Shares or Performance Units. 
 (aa) “Performance Award Formula” means, for any Performance Award, a formula or table established by the Committee
pursuant to Section 9.3 of the Plan which provides the basis for computing the value of a Performance Award at one or more threshold levels of attainment of the applicable Performance Goal(s) measured as of the end of the applicable Performance
Period. 
 (bb) “Performance Goal” means a performance goal established by the Committee pursuant to
Section 9.3 of the Plan. 
 (cc) “Performance Period” means a period established by the Committee
pursuant to Section 9.3 of the Plan at the end of which one or more Performance Goals are to be measured. 
 (dd)
“Performance Share” means a bookkeeping entry representing a right granted to a Participant pursuant to Section 9 of the Plan to receive a payment equal to the value of a Performance Share, as determined by
the Committee, based on performance. 
 (ee) “Performance Unit” means a bookkeeping entry representing
a right granted to a Participant pursuant to Section 9 of the Plan to receive a payment equal to the value of a Performance Unit, as determined by the Committee, based upon performance. 
 (ff) “Prior Plan Options” means any option or other award granted by the Company which is subject to vesting or
repurchase by the Company, including specifically, all such options and awards granted pursuant to the Company’s 2002 Equity Incentive Plan, Director Stock Option Plan, Scientific Advisory Board/Consultants Stock Option Plan, 1995 Stock Option
Plan and the Variagenics 1997 Employee, Director & Consultant Stock Option Plan which is outstanding on or after the Effective Date. 
 (gg) “Restricted Stock Award” means an Award of a Restricted Stock Bonus or a Restricted Stock Purchase Right. 
 (hh) “Restricted Stock Bonus” means Stock granted to a Participant pursuant to Section 8 of the Plan. 
  

 A-3 

 (ii) “Restricted Stock Purchase Right” means a right to purchase
Stock granted to a Participant pursuant to Section 8 of the Plan. 
 (jj) “Restricted Stock Unit”
or “Stock Unit” means a bookkeeping entry representing a right granted to a Participant pursuant to Section 10 of the Plan to receive a share of Stock on a date determined in accordance with the provisions
of Section 10 and the Participant’s Award Agreement. 
 (kk) “Restriction Period” means the
period established in accordance with Section 8.5 of the Plan during which shares subject to a Restricted Stock Award are subject to Vesting Conditions. 
 (ll) “Retirement” means a Participant’s termination of Service, if as of the date of such termination, the Participant has reached the age of fifty-eight (58) and has
completed eight (8) years of continuous Service to the Participating Company Group. A Participant who terminates Service with the Participating Company Group and resumes Service more than six (6) months after his or her original
termination date, will not have his or her Service with the Participant Company Group prior to his or her original termination date count for purposes of determining Retirement. Notwithstanding the foregoing, the Board shall have the discretion to
determine on a case by case basis whether such prior Service with the Participant Company Group may be counted for purposes of Retirement. The Board will notify any rehired Participant if the Board has determined such prior Service will count
towards Retirement, and in the absence of such notification from the Board, such Service shall not be counted for purposes of Retirement. 
 (mm) “Rule 16b-3” means Rule 16b-3 under the Exchange Act, as amended from time to time, or any successor rule or regulation. 
 (nn) “SAR” or “Stock Appreciation Right” means a bookkeeping entry
representing, for each share of Stock subject to such SAR, a right granted to a Participant pursuant to Section 7 of the Plan to receive payment of an amount equal to the excess, if any, of the Fair Market Value of a share of Stock on the date
of exercise of the SAR over the exercise price. 
 (oo) “Section 162(m)” means Section 162(m)
of the Code. 
 (pp) “Securities Act” means the Securities Act of 1933, as amended. 
 (qq) “Service” means a Participant’s employment or service with the Participating Company Group, whether in
the capacity of an Employee, a Director or a Consultant. A Participant’s Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders such Service or a change in the Participating
Company for which the Participant renders such Service, provided that there is no interruption or termination of the Participant’s Service. Furthermore, a Participant’s Service shall not be deemed to have terminated if the Participant
takes any military leave, sick leave, or other bona fide leave of absence approved by the Company. However, if any such leave taken by a Participant exceeds ninety (90) days, then on the one hundred eighty-first (181st) day following the
commencement of such leave any Incentive Stock Option held by the Participant shall cease to be treated as an Incentive Stock Option and instead shall be treated thereafter as a Nonstatutory Stock Option, unless the Participant’s right to
return to Service with the Participating Company Group is guaranteed by statute or contract. Notwithstanding the foregoing, unless otherwise designated by the Company or required by law, a leave of absence shall not be treated as Service for
purposes of determining vesting under the Participant’s Award Agreement. A Participant’s Service shall be deemed to have terminated either upon an actual termination of Service or upon the entity for which the Participant performs Service
ceasing to be a Participating Company. In addition, a Participant’s Service shall be deemed to have terminated if, in the Committee’s sole discretion, the Participant’s employment relationship is transferred to an Affiliate or
Subsidiary Corporation and the Participant is offered a replacement equity award from the Affiliate or Subsidiary Corporation. Subject to the foregoing, the Company, in its discretion, shall determine whether the Participant’s Service has
terminated and the effective date of such termination. 
 (rr) “Stock” means the common stock of the
Company, as adjusted from time to time in accordance with Section 4.2 of the Plan. 
  

 A-4 

 (ss) “Subsidiary Corporation” means any present or future
“subsidiary corporation” of the Company, as defined in Section 424(f) of the Code. 
 (tt) “Ten Percent
Owner” means a Participant who, at the time an Incentive Stock Option is granted to the Participant, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of a
Participating Company (other than an Affiliate) within the meaning of Section 422(b)(6) of the Code. 
 (uu) “Vesting
Conditions” mean those conditions established in accordance with Section 8.5 or Section 10.3 of the Plan prior to the satisfaction of which shares subject to a Restricted Stock Award or Restricted Stock Unit Award,
respectively, remain subject to forfeiture or a repurchase option in favor of the Company upon the Participant’s termination of Service. 
 2.2 Construction. Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan. Except when otherwise indicated by the context, the singular shall
include the plural and the plural shall include the singular. Use of the term “or” is not intended to be exclusive, unless the context clearly requires otherwise. 
  

	3.	ADMINISTRATION. 

 3.1
Administration by the Committee. The Plan shall be administered by the Committee. All questions of interpretation of the Plan or of any Award shall be determined by the Committee, and such determinations shall be final and binding upon all
persons having an interest in the Plan or such Award. 
 3.2 Authority of Officers. Any Officer shall have the authority to act
on behalf of the Company with respect to any matter, right, obligation, determination or election which is the responsibility of or which is allocated to the Company herein, provided the Officer has apparent authority with respect to such matter,
right, obligation, determination or election. The Board may, in its discretion, delegate to a committee comprised of one or more Officers the authority to grant one or more Awards, without further approval of the Board or the Committee, to any
Employee, other than a person who, at the time of such grant, is an Insider; provided, however, that (a) such Awards shall not be granted for shares in excess of the maximum aggregate number of shares of Stock authorized for issuance pursuant
to Section 4.1, (b) the exercise price per share of each Option shall be not less than the Fair Market Value per share of the Stock on the effective date of grant (or, if the Stock has not traded on such date, on the last day preceding the
effective date of grant on which the Stock was traded), and (c) each such Award shall be subject to the terms and conditions of the appropriate standard form of Award Agreement approved by the Board or the Committee and shall conform to the
provisions of the Plan and such other guidelines as shall be established from time to time by the Board or the Committee. 
 3.3
Administration with Respect to Insiders. With respect to participation by Insiders in the Plan, at any time that any class of equity security of the Company is registered pursuant to Section 12 of the Exchange Act, the Plan shall be
administered in compliance with the requirements, if any, of Rule 16b-3. 
 3.4 Committee Complying with
Section 162(m). If the Company is a “publicly held corporation” within the meaning of Section 162(m), the Board may establish a Committee of “outside directors” within the meaning of Section 162(m) to
approve the grant of any Award which might reasonably be anticipated to result in the payment of employee remuneration that would otherwise exceed the limit on employee remuneration deductible for income tax purposes pursuant to Section 162(m).

 3.5 Powers of the Committee. In addition to any other powers set forth in the Plan and subject to the provisions
of the Plan, the Committee shall have the full and final power and authority, in its discretion: 
 (a) to determine the persons to whom, and
the time or times at which, Awards shall be granted and the number of shares of Stock or units to be subject to each Award; 
 (b) to
determine the type of Award granted and to designate Options as Incentive Stock Options, Nonstatutory Stock Options or Indexed Options; 
  

 A-5 

 (c) to determine the Fair Market Value of shares of Stock or other property; 
 (d) to determine the terms, conditions and restrictions applicable to each Award (which need not be identical) and any shares acquired pursuant thereto,
including, without limitation, (i) the exercise or purchase price of shares purchased pursuant to any Award, (ii) the method of payment for shares purchased pursuant to any Award, (iii) the method for satisfaction of any tax
withholding obligation arising in connection with Award, including by the withholding or delivery of shares of Stock, (iv) the timing, terms and conditions of the exercisability or vesting of any Award or any shares acquired pursuant thereto,
(v) the Performance Award Formula and Performance Goals applicable to any Award and the extent to which such Performance Goals have been attained, (vi) the time of the expiration of any Award, (vii) the effect of the
Participant’s termination of Service on any of the foregoing, and (viii) all other terms, conditions and restrictions applicable to any Award or shares acquired pursuant thereto not inconsistent with the terms of the Plan; 
 (e) to determine whether an Award of Restricted Stock Units, SARs, Performance Shares or Performance Units will be settled in shares of Stock, cash, or
in any combination thereof; 
 (f) to approve one or more forms of Award Agreement; 
 (g) to amend, modify, extend, cancel or renew any Award or to waive any restrictions or conditions applicable to any Award or any shares acquired
pursuant thereto; 
 (h) to accelerate, continue, extend or defer the exercisability or vesting of any Award or any shares acquired pursuant
thereto, including with respect to the period following a Participant’s termination of Service; 
 (i) to prescribe, amend or rescind
rules, guidelines and policies relating to the Plan, or to adopt sub-plans or supplements to, or alternative versions of, the Plan, including, without limitation, as the Committee deems necessary or desirable to comply with the laws or regulations
of or to accommodate the tax policy, accounting principles or custom of, foreign jurisdictions whose citizens may be granted Awards; 
 (j)
to authorize, in conjunction with any applicable Company deferred compensation plan, that the receipt of cash or Stock subject to any Award under this Plan, may be deferred under the terms and conditions of such Company deferred compensation plan;
and 
 (k) to correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award Agreement and to make all other
determinations and take such other actions with respect to the Plan or any Award as the Committee may deem advisable to the extent not inconsistent with the provisions of the Plan or applicable law. 
 3.6 No Repricing. Without the affirmative vote of holders of a majority of the shares of Stock cast in person or by proxy at a meeting of the
stockholders of the Company at which a quorum representing a majority of all outstanding shares of Stock is present or represented by proxy, the Board shall not approve a program providing for either (a) the cancellation of outstanding Options
and/or SARs and the grant in substitution therefore of any new Awards, including specifically any new Options and/or SARs having a lower exercise price or (b) the amendment of outstanding Options and/or SARs to reduce the exercise price
thereof. This paragraph shall not be construed to apply to “issuing or assuming a stock option in a transaction to which section 424(a) applies,” within the meaning of Section 424 of the Code. 
 3.7 No Restricted Stock Award Acceleration. Notwithstanding any provision of the Plan to the contrary, no Restricted Stock Award may be
granted which provides, or subsequently amended to provide, for (i) any acceleration of vesting for any reason other than upon a Change in Control or after the Participant’s death or Disability and (ii) vesting of one hundred percent
(100%) of any such Restricted Stock Award prior to the passage of three (3) years of Service (unless such Restricted Stock Award will vest in accordance with the satisfaction of any Performance Measure set forth in Section 9.4).

 3.8 Indemnification. In addition to such other rights of indemnification as they may have as members of the Board or the
Committee or as officers or employees of the Participating Company Group, members of the 
  

 A-6 

 Board or the Committee and any officers or employees of the Participating Company Group to whom authority to act for the
Board, the Committee or the Company is delegated shall be indemnified by the Company against all reasonable expenses, including attorneys’ fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding,
or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any right granted hereunder, and against all amounts paid by them in
settlement thereof (provided such settlement is approved by independent legal counsel selected by the Company) or paid by them in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall
be adjudged in such action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct in duties; provided, however, that within sixty (60) days after the institution of such action, suit or
proceeding, such person shall offer to the Company, in writing, the opportunity at its own expense to handle and defend the same. 
  

	4.	SHARES SUBJECT TO PLAN. 

 4.1 Maximum Number of Shares Issuable. Subject to adjustment as provided in Section 4.2, the maximum aggregate number of shares of Stock
that may be granted under the Plan shall be Eleven Million Four Hundred and Four Thousand and Eighty-Five (11,404,085), reduced at any time by the number of shares subject to the Prior Plan Options. Such shares shall consist of authorized but
unissued or reacquired shares of Stock or any combination thereof. If any outstanding Award, including any Prior Plan Options, for any reason expires or is terminated or canceled without having been exercised or settled in full, or if shares of
Stock acquired pursuant to an Award subject to forfeiture or repurchase, including any Prior Plan Options, are forfeited or repurchased by the Company, the shares of Stock allocable to the terminated portion of such Award, including any Prior Plan
Options, or such forfeited or repurchased shares of Stock shall again be available for grant under the Plan. Shares of Stock shall not be deemed to have been granted pursuant to the Plan with respect to any portion of an Award that is settled in
cash. Notwithstanding anything to the contrary in this Section 4.1, the following shares of Stock shall not be available for reissuance under the Plan: (i) shares of Stock with respect to which the Participant has received the benefits of
ownership (other than voting rights), either in the form of dividends, shares sold pursuant to a Cashless Exercise described in Section 6.3(a) or otherwise; (ii) shares of Stock which are withheld from any Award or payment under the Plan
to satisfy tax withholding obligations pursuant to Section 15.2; (iii) shares of Stock which are surrendered by any Participant (through a Cashless Exercise, actual delivery of the shares or attestation of ownership) to fulfill tax
withholding obligations or to pay the applicable exercise price for any Award; and (iv) shares of Stock subject to the grant of a SAR which are not issued upon settlement of the SAR. 
 4.2 Adjustments for Changes in Capital Structure. Subject to any required action by the stockholders of the Company, in the
event of any change in the Stock effected without receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split,
split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the stockholders of the Company in a form other than
Stock (excepting normal cash dividends) that has a material effect on the Fair Market Value of shares of Stock, appropriate adjustments shall be made in the number and class of shares subject to the Plan and to any outstanding Awards, and in the
exercise or purchase price per share under any outstanding Award in order to prevent dilution or enlargement of Participants’ rights under the Plan. For purposes of the foregoing, conversion of any convertible securities of the Company shall
not be treated as “effected without receipt of consideration by the Company.” Any fractional share resulting from an adjustment pursuant to this Section 4.2 shall be rounded down to the nearest whole number, and in no event may the
exercise or purchase price under any Award be decreased to an amount less than the par value, if any, of the stock subject to such Award. The adjustments determined by the Committee pursuant to this Section 4.2 shall be final, binding and
conclusive. 
  

	5.	ELIGIBILITY AND AWARD LIMITATIONS. 

 5.1 Persons Eligible for Awards. Awards may be granted only to Employees, Consultants and Directors. For purposes of the foregoing sentence,
“Employees,” “Consultants” and “Directors” shall include prospective Employees, prospective Consultants and prospective Directors to whom Awards are granted in connection with 
  

 A-7 

 written offers of an employment or other service relationship with the Participating Company Group; provided, however,
that no Stock subject to any such Award shall vest, become exercisable or be issued prior to the date on which such person commences Service. 
 5.2 Participation. Awards are granted solely at the discretion of the Committee. Eligible persons may be granted more than one (1) Award. However, eligibility in accordance with this Section shall not entitle any person to
be granted an Award, or, having been granted an Award, to be granted an additional Award. 
 5.3 Incentive Stock Option Limitations.

 (a) Persons Eligible. An Incentive Stock Option may be granted only to a person who, on the effective date of grant, is
an Employee of the Company, a Parent Corporation or a Subsidiary Corporation (each being an “ISO-Qualifying Corporation”). Any person who is not an Employee of an ISO-Qualifying Corporation on the effective date of the
grant of an Option to such person may be granted only a Nonstatutory Stock Option. An Incentive Stock Option granted to a prospective Employee upon the condition that such person become an Employee of an ISO-Qualifying Corporation shall be deemed
granted effective on the date such person commences Service with an ISO-Qualifying Corporation, with an exercise price determined as of such date in accordance with Section 6.1. 
 (b) Fair Market Value Limitation. To the extent that options designated as Incentive Stock Options (granted under all stock option
plans of the Participating Company Group, including the Plan) become exercisable by a Participant for the first time during any calendar year for stock having a Fair Market Value greater than One Hundred Thousand dollars ($100,000), the portion of
such options which exceeds such amount shall be treated as Nonstatutory Stock Options. For purposes of this Section, options designated as Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair
Market Value of stock shall be determined as of the time the option with respect to such stock is granted. If the Code is amended to provide for a different limitation from that set forth in this Section, such different limitation shall be deemed
incorporated herein effective as of the date and with respect to such Options as required or permitted by such amendment to the Code. If an Option is treated as an Incentive Stock Option in part and as a Nonstatutory Stock Option in part by reason
of the limitation set forth in this Section, the Participant may designate which portion of such Option the Participant is exercising. In the absence of such designation, the Participant shall be deemed to have exercised the Incentive Stock Option
portion of the Option first. Upon exercise, shares issued pursuant to each such portion shall be separately identified. 
 5.4 Award
Limits. 
 (a) Aggregate Limit on Restricted Stock Awards and Performance Awards. Subject to adjustment as provided in
Section 4.2, in no event shall more than One Million (1,000,000) shares of Stock in the aggregate be issued under the Plan pursuant to the exercise or settlement of Restricted Stock Awards and Performance Awards. 
 (b) Section 162(m) Award Limits. The following limits shall apply to the grant of any Award if, at the time of grant, the Company
is a “publicly held corporation” within the meaning of Section 162(m). 
 (i) Options and SARs. Subject to
adjustment as provided in Section 4.2, no Employee shall be granted within any fiscal year of the Company one or more Options or Freestanding SARs which in the aggregate are for more than Seven Hundred and Fifty Thousand (750,000) shares
of Stock, provided, however, that the Company may make an additional one-time grant to any newly-hired Employee of an Option and/or SAR for the purchase of up to an additional Five Hundred Thousand (500,000) shares of Stock. An Option which is
canceled (or a Freestanding SAR as to which the exercise price is reduced to reflect a reduction in the Fair Market Value of the Stock) in the same fiscal year of the Company in which it was granted shall continue to be counted against such limit
for such fiscal year. 
 (ii) Restricted Stock Awards and Restricted Stock Units. Subject to adjustment as provided in
Section 4.2, no Employee shall be granted within any fiscal year of the Company one or more 
  

 A-8 

 Restricted Stock Awards or Restricted Stock Units, subject to Vesting Conditions based on the attainment of Performance
Goals, for more than Four Hundred Thousand (400,000) shares of Stock, provided, however, that the Company may make an additional one-time grant to any newly-hired Employee of a Restricted Stock Award or Restricted Stock Units of up to an
additional One Hundred and Fifty Thousand (150,000) shares of Stock. 
 (iii) Performance Awards. Subject to adjustment as
provided in Section 4.2, no Employee shall be granted (A) Performance Shares which could result in such Employee receiving more than Four Hundred Thousand (400,000) shares of Stock for each full fiscal year of the Company contained in
the Performance Period for such Award, or (B) Performance Units which could result in such Employee receiving more than Two Million dollars ($2,000,000) for each full fiscal year of the Company contained in the Performance Period for such
Award. No Participant may be granted more than one Performance Award for the same Performance Period. 
  

	6.	TERMS AND CONDITIONS OF OPTIONS. 

 Options shall be evidenced by Award Agreements specifying the number of shares of Stock covered thereby, in such form as the Committee shall from time to
time establish. No Option or purported Option shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Options may incorporate all or any of the terms of the Plan by
reference and shall comply with and be subject to the following terms and conditions: 
 6.1 Exercise Price. The
exercise price for each Option shall be established in the discretion of the Committee; provided, however, that (a) the exercise price per share shall be not less than the Fair Market Value of a share of Stock on the effective date of grant of
the Option, (b) no Incentive Stock Option granted to a Ten Percent Owner shall have an exercise price per share less than one hundred ten percent (110%) of the Fair Market Value of a share of Stock on the effective date of grant of the
Option, and (c) notwithstanding anything to the contrary in this Section 6.1, in the case of an Indexed Option, the Committee shall determine the exercise price of such Indexed Option and the terms and conditions that affect, if any, any
adjustments to the exercise price of such Indexed Option. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than the minimum exercise price set forth above if such Option is granted pursuant to an assumption or
substitution for another option in a manner qualifying under the provisions of Section 424(a) of the Code. 
 6.2 Exercisability and
Term of Options. Options shall be exercisable at such time or times, or upon such event or events, and subject to such terms, conditions, performance criteria and restrictions as shall be determined by the Committee and set
forth in the Award Agreement evidencing such Option; provided, however, that (a) no Option shall be exercisable after the expiration of ten (10) years after the effective date of grant of such Option, (b) no Incentive Stock Option
granted to a Ten Percent Owner shall be exercisable after the expiration of five (5) years after the effective date of grant of such Option, and (c) no Option granted to a prospective Employee, prospective Consultant or prospective
Director may become exercisable prior to the date on which such person commences Service. Subject to the foregoing, unless otherwise specified by the Committee in the grant of an Option, any Option granted hereunder shall terminate ten
(10) years after the effective date of grant of the Option, unless earlier terminated in accordance with its provisions. 
 6.3
Payment of Exercise Price. 
 (a) Forms of Consideration Authorized. Except as otherwise provided below, payment of
the exercise price for the number of shares of Stock being purchased pursuant to any Option shall be made (i) in cash, by check or in cash equivalent, (ii) by tender to the Company, or attestation to the ownership, of shares of Stock owned
by the Participant having a Fair Market Value not less than the exercise price, (iii) by delivery of a properly executed notice of exercise together with irrevocable instructions to a broker providing for the assignment to the Company of the
proceeds of a sale or loan with respect to some or all of the shares being acquired upon the exercise of the Option (including, without limitation, through an exercise 
  

 A-9 

 complying with the provisions of Regulation T as promulgated from time to time by the Board of Governors of the
Federal Reserve System) (a “Cashless Exercise”), (iv) by such other consideration as may be approved by the Committee from time to time to the extent permitted by applicable law, or (v) by any combination
thereof. The Committee may at any time or from time to time grant Options which do not permit all of the foregoing forms of consideration to be used in payment of the exercise price or which otherwise restrict one or more forms of consideration.

 (b) Limitations on Forms of Consideration. 
 (i) Tender of Stock. Notwithstanding the foregoing, an Option may not be exercised by tender to the Company, or attestation to the ownership, of shares of Stock to the extent such tender or attestation
would constitute a violation of the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock. Unless otherwise provided by the Committee, an Option may not be exercised by tender to the Company, or
attestation to the ownership, of shares of Stock unless such shares either have been owned by the Participant for more than six (6) months (and not used for another Option exercise by attestation during such period) or were not acquired,
directly or indirectly, from the Company. 
 (ii) Cashless Exercise. The Company reserves, at any and all times, the right, in
the Company’s sole and absolute discretion, to establish, decline to approve or terminate any program or procedures for the exercise of Options by means of a Cashless Exercise, including with respect to one or more Participants specified by the
Company notwithstanding that such program or procedures may be available to other Participants. 
 6.4 Effect of Termination of
Service. An Option shall be exercisable after a Participant’s termination of Service to such extent and during such period as determined by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Option.

 6.5 Transferability of Options. During the lifetime of the Participant, an Option shall be exercisable only by the Participant
or the Participant’s guardian or legal representative. Prior to the issuance of shares of Stock upon the exercise of an Option, the Option shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment,
pledge, encumbrance, or garnishment by creditors of the Participant or the Participant’s beneficiary, except transfer by will or by the laws of descent and distribution. Notwithstanding the foregoing, to the extent permitted by the Committee,
in its discretion, and set forth in the Award Agreement evidencing such Option, a Nonstatutory Stock Option shall be assignable or transferable subject to the applicable limitations, if any, described in the General Instructions to Form S-8
Registration Statement under the Securities Act. Notwithstanding any of the foregoing, the Board may permit further transferability of any Option, on a general or specific basis, and may impose conditions and limitations on any permitted
transferability. 
  

	7.	TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS.

 Stock Appreciation Rights shall be evidenced by Award Agreements specifying the number of shares of Stock subject to the
Award, in such form as the Committee shall from time to time establish. No SAR or purported SAR shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing SARs may
incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: 
 7.1 Types of SARs Authorized. SARs may be granted in tandem with all or any portion of a related Option (a “Tandem SAR”) or may be granted independently of any Option (a
“Freestanding SAR”). A Tandem SAR may be granted either concurrently with the grant of the related Option or at any time thereafter prior to the complete exercise, termination, expiration or cancellation of such
related Option. 
 7.2 Exercise Price. The exercise price for each SAR shall be established in the discretion of the Committee;
provided, however, that (a) the exercise price per share subject to a Tandem SAR shall be the 
  

 A-10 

 exercise price per share under the related Option and (b) the exercise price per share subject to a Freestanding SAR
shall be not less than the Fair Market Value of a share of Stock on the effective date of grant of the SAR. 
 7.3 Exercisability and Term
of SARs. 
 (a) Tandem SARs. Tandem SARs shall be exercisable only at the time and to the extent, and only to the
extent, that the related Option is exercisable, subject to such provisions as the Committee may specify where the Tandem SAR is granted with respect to less than the full number of shares of Stock subject to the related Option. The Committee may, in
its discretion, provide in any Award Agreement evidencing a Tandem SAR that such SAR may not be exercised without the advance approval of the Company and, if such approval is not given, then the Option shall nevertheless remain exercisable in
accordance with its terms. A Tandem SAR shall terminate and cease to be exercisable no later than the date on which the related Option expires or is terminated or canceled. Upon the exercise of a Tandem SAR with respect to some or all of the shares
subject to such SAR, the related Option shall be canceled automatically as to the number of shares with respect to which the Tandem SAR was exercised. Upon the exercise of an Option related to a Tandem SAR as to some or all of the shares subject to
such Option, the related Tandem SAR shall be canceled automatically as to the number of shares with respect to which the related Option was exercised. 
 (b) Freestanding SARs. Freestanding SARs shall be exercisable at such time or times, or upon such event or events, and subject to such terms, conditions, performance criteria and restrictions as
shall be determined by the Committee and set forth in the Award Agreement evidencing such SAR; provided, however, that no Freestanding SAR shall be exercisable after the expiration of ten (10) years after the effective date of grant of such
SAR. 
 7.4 Exercise of SARs. Upon the exercise (or deemed exercise pursuant to Section 7.5) of a SAR, the Participant (or
the Participant’s legal representative or other person who acquired the right to exercise the SAR by reason of the Participant’s death) shall be entitled to receive payment of an amount for each share with respect to which the SAR is
exercised equal to the excess, if any, of the Fair Market Value of a share of Stock on the date of exercise of the SAR over the exercise price. Payment of such amount shall be made in cash, shares of Stock, or any combination thereof as determined
by the Committee. Unless otherwise provided in the Award Agreement evidencing such SAR, payment shall be made in a lump sum as soon as practicable following the date of exercise of the SAR. The Award Agreement evidencing any SAR may provide for
deferred payment in a lump sum or in installments. When payment is to be made in shares of Stock, the number of shares to be issued shall be determined on the basis of the Fair Market Value of a share of Stock on the date of exercise of the SAR. For
purposes of Section 7, a SAR shall be deemed exercised on the date on which the Company receives notice of exercise from the Participant. 
 7.5 Deemed Exercise of SARs. If, on the date on which a SAR would otherwise terminate or expire, the SAR by its terms remains exercisable immediately prior to such termination or expiration and, if so exercised, would result in
a payment to the holder of such SAR, then any portion of such SAR which has not previously been exercised shall automatically be deemed to be exercised as of such date with respect to such portion. 
 7.6 Effect of Termination of Service. Subject to earlier termination of the SAR as otherwise provided herein a SAR shall be exercisable after
a Participant’s termination of Service to such extent and during such period as determined by the Committee, in its discretion, and set forth in the Award Agreement evidencing such SAR and thereafter shall terminate. 
 7.7 Nontransferability of SARs. During the lifetime of the Participant, a SAR shall be exercisable only by the Participant or the
Participant’s guardian or legal representative. Prior to the exercise of a SAR, the SAR shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of
the Participant or the Participant’s beneficiary, except transfer by will or by the laws of descent and distribution. Notwithstanding any of the foregoing, the Board may permit further transferability of any SAR, on a general or specific basis,
and may impose conditions and limitations on any permitted transferability. 
  

 A-11 

	8.	TERMS AND CONDITIONS OF RESTRICTED STOCK AWARDS.

 Restricted Stock Awards shall be evidenced by Award Agreements specifying whether the Award is a Restricted Stock Bonus or a
Restricted Stock Purchase Right and the number of shares of Stock subject to the Award, in such form as the Committee shall from time to time establish. No Restricted Stock Award or purported Restricted Stock Award shall be a valid and binding
obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Restricted Stock Awards may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the
following terms and conditions: 
 8.1 Types of Restricted Stock Awards Authorized. Restricted Stock Awards may be in the form of
either a Restricted Stock Bonus or a Restricted Stock Purchase Right. Restricted Stock Awards may be granted upon such conditions as the Committee shall determine, including, without limitation, upon the attainment of one or more Performance Goals
described in Section 9.4. If either the grant of a Restricted Stock Award or the lapsing of the Restriction Period is to be contingent upon the attainment of one or more Performance Goals, the Committee shall follow procedures substantially
equivalent to those set forth in Sections 9.3 through 9.5(a). 
 8.2 Purchase Price. The purchase price for shares of Stock
issuable under each Restricted Stock Purchase Right shall be established by the Committee in its discretion. No monetary payment (other than applicable tax withholding) shall be required as a condition of receiving shares of Stock pursuant to a
Restricted Stock Bonus, the consideration for which shall be services actually rendered to a Participating Company or for its benefit. Notwithstanding the foregoing, the Participant shall furnish consideration in the form of cash or past services
rendered to a Participating Company or for its benefit having a value not less than the par value of the shares of Stock subject to such Restricted Stock Award. 
 8.3 Purchase Period. A Restricted Stock Purchase Right shall be exercisable within a period established by the Committee, which shall in no event exceed thirty (30) days from the effective date of the
grant of the Restricted Stock Purchase Right; provided, however, that no Restricted Stock Purchase Right granted to a prospective Employee, prospective Consultant or prospective Director may become exercisable prior to the date on which such person
commences Service. 
 8.4 Payment of Purchase Price. Except as otherwise provided below, payment of the purchase price for the
number of shares of Stock being purchased pursuant to any Restricted Stock Purchase Right shall be made (a) in cash, by check, or in cash equivalent, (b) by such other consideration as may be approved by the Committee from time to time to
the extent permitted by applicable law, or (c) by any combination thereof. The Committee may at any time or from time to time grant Restricted Stock Purchase Rights which do not permit all of the foregoing forms of consideration to be used in
payment of the purchase price or which otherwise restrict one or more forms of consideration. Restricted Stock Bonuses shall be issued in consideration for past services actually rendered to a Participating Company or for its benefit. 
 8.5 Vesting and Restrictions on Transfer. Shares issued pursuant to any Restricted Stock Award may or may not be made subject to Vesting
Conditions based upon the satisfaction of such Service requirements, conditions, restrictions or performance criteria, including, without limitation, Performance Goals as described in Section 9.4, as shall be established by the Committee and
set forth in the Award Agreement evidencing such Award. During any Restriction Period in which shares acquired pursuant to a Restricted Stock Award remain subject to Vesting Conditions, such shares may not be sold, exchanged, transferred, pledged,
assigned or otherwise disposed of other than pursuant to an Ownership Change Event, as defined in Section 13.1, or as provided in Section 8.8. Upon request by the Company, each Participant shall execute any agreement evidencing such
transfer restrictions prior to the receipt of shares of Stock hereunder and shall promptly present to the Company any and all certificates representing shares of Stock acquired hereunder for the placement on such certificates of appropriate legends
evidencing any such transfer restrictions. 
 8.6 Voting Rights; Dividends and Distributions. Except as provided in this Section,
Section 8.5 and any Award Agreement, during the Restriction Period applicable to shares subject to a Restricted Stock Award, the Participant shall have all of the rights of a stockholder of the Company holding shares of Stock, including the

  

 A-12 

 right to vote such shares and to receive all dividends and other distributions paid with respect to such shares. However,
in the event of a dividend or distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of the Company as described in Section 4.2, then any and all new, substituted or additional securities or
other property (other than normal cash dividends) to which the Participant is entitled by reason of the Participant’s Restricted Stock Award shall be immediately subject to the same Vesting Conditions as the shares subject to the Restricted
Stock Award with respect to which such dividends or distributions were paid or adjustments were made. 
 8.7 Effect of Termination of
Service. Unless otherwise provided by the Committee in the grant of a Restricted Stock Award and set forth in the Award Agreement, if a Participant’s Service terminates for any reason, whether voluntary or involuntary (including the
Participant’s death or Disability), then (a) the Company shall have the option to repurchase for the purchase price paid by the Participant any shares acquired by the Participant pursuant to a Restricted Stock Purchase Right which remain
subject to Vesting Conditions as of the date of the Participant’s termination of Service and (b) the Participant shall forfeit to the Company any shares acquired by the Participant pursuant to a Restricted Stock Bonus which remain subject
to Vesting Conditions as of the date of the Participant’s termination of Service. The Company shall have the right to assign at any time any repurchase right it may have, whether or not such right is then exercisable, to one or more persons as
may be selected by the Company. 
 8.8 Nontransferability of Restricted Stock Award Rights. Prior to the issuance of shares of
Stock pursuant to a Restricted Stock Award, rights to acquire such shares shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance or garnishment by creditors of the Participant or the
Participant’s beneficiary, except transfer by will or the laws of descent and distribution. All rights with respect to a Restricted Stock Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such
Participant or the Participant’s guardian or legal representative. 
  

	9.	TERMS AND CONDITIONS OF PERFORMANCE AWARDS. 

 Performance Awards shall be evidenced by Award Agreements in such form as the Committee shall from time to time establish. No Performance Award or
purported Performance Award shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Performance Awards may incorporate all or any of the terms of the Plan by reference
and shall comply with and be subject to the following terms and conditions: 
 9.1 Types of Performance Awards
Authorized. Performance Awards may be in the form of either Performance Shares or Performance Units. Each Award Agreement evidencing a Performance Award shall specify the number of Performance Shares or Performance Units subject thereto,
the Performance Award Formula, the Performance Goal(s) and Performance Period applicable to the Award, and the other terms, conditions and restrictions of the Award. 
 9.2 Initial Value of Performance Shares and Performance Units. Unless otherwise provided by the Committee in granting a Performance Award, each Performance Share shall have an initial value equal to the
Fair Market Value of one (1) share of Stock, subject to adjustment as provided in Section 4.2, on the effective date of grant of the Performance Share, and each Performance Unit shall have an initial value of one hundred dollars ($100).
The final value payable to the Participant in settlement of a Performance Award determined on the basis of the applicable Performance Award Formula will depend on the extent to which Performance Goals established by the Committee are attained within
the applicable Performance Period established by the Committee. 
 9.3 Establishment of Performance Period, Performance Goals and
Performance Award Formula. In granting each Performance Award, the Committee shall establish in writing the applicable Performance Period, Performance Award Formula and one or more Performance Goals which, when measured at the end of the
Performance Period, shall determine on the basis of the Performance Award Formula the final value of the 
  

 A-13 

 Performance Award to be paid to the Participant. Unless otherwise permitted in compliance with the requirements under
Section 162(m) with respect to “performance-based compensation,” the Committee shall establish the Performance Goal(s) and Performance Award Formula applicable to each Performance Award no later than the earlier of (a) the date
ninety (90) days after the commencement of the applicable Performance Period or (b) the date on which 25% of the Performance Period has elapsed, and, in any event, at a time when the outcome of the Performance Goals remains substantially
uncertain. Once established, the Performance Goals and Performance Award Formula shall not be changed during the Performance Period. The Company shall notify each Participant granted a Performance Award of the terms of such Award, including the
Performance Period, Performance Goal(s) and Performance Award Formula. 
 9.4 Measurement of Performance Goals. Performance Goals
shall be established by the Committee on the basis of targets to be attained ( “Performance Targets”) with respect to one or more measures of business or financial performance (each, a “Performance
Measure”), subject to the following: 
 (a) Performance Measures. Performance Measures shall have the
same meanings as used in the Company’s financial statements, or, if such terms are not used in the Company’s financial statements, they shall have the meaning applied pursuant to generally accepted accounting principles, or as used
generally in the Company’s industry. Performance Measures shall be calculated with respect to the Company and each Subsidiary Corporation consolidated therewith for financial reporting purposes or such division or other business unit as may be
selected by the Committee. For purposes of the Plan, the Performance Measures applicable to a Performance Award shall be calculated in accordance with generally accepted accounting principles, but prior to the accrual or payment of any Performance
Award for the same Performance Period and excluding the effect (whether positive or negative) of any change in accounting standards or any extraordinary, unusual or nonrecurring item, as determined by the Committee, occurring after the establishment
of the Performance Goals applicable to the Performance Award. Performance Measures may be one or more of the following, or a combination of the any of the following, as determined by the Committee: 
  

			
	 (i)
	  	revenue;
	 (ii)
	  	gross margin;
	 (iii)
	  	operating margin;
	 (iv)
	  	operating income;
	 (v)
	  	pre-tax profit;
	 (vi)
	  	earnings before interest, taxes and depreciation;
	 (vii)
	  	net income;
	 (viii)
	  	cash flow;
	 (ix)
	  	expenses;
	 (x)
	  	the market price of the Stock;
	 (xi)
	  	earnings per share;
	 (xii)
	  	return on stockholder equity;
	 (xiii)
	  	return on capital;
	 (xiv)
	  	return on net assets;
	 (xv)
	  	economic value added;
	 (xvi)
	  	number of customers;
	 (xvii)
	  	market share;
	 (xviii)
	  	return on investment
	 (xix)
	  	profit after tax
	 (xx)
	  	product approval; and
	 (xxi)
	  	customer satisfaction.

 (b) Performance Targets. Performance Targets may include a minimum, maximum,
target level and intermediate levels of performance, with the final value of a Performance Award determined under the 
  

 A-14 

 applicable Performance Award Formula by the level attained during the applicable Performance Period. A Performance Target
may be stated as an absolute value or as a value determined relative to a standard selected by the Committee. 
 9.5 Settlement of
Performance Awards. 
 (a) Determination of Final Value. As soon as practicable following the completion of the
Performance Period applicable to a Performance Award, the Committee shall certify in writing the extent to which the applicable Performance Goals have been attained and the resulting final value of the Award earned by the Participant and to be paid
upon its settlement in accordance with the applicable Performance Award Formula. 
 (b) Discretionary Adjustment of Award
Formula. In its discretion, the Committee may, either at the time it grants a Performance Award or at any time thereafter, provide for the positive or negative adjustment of the Performance Award Formula applicable to a Performance
Award granted to any Participant who is not a “covered employee” within the meaning of Section 162(m) (a “Covered Employee”) to reflect such Participant’s individual performance in his or her
position with the Company or such other factors as the Committee may determine. If permitted under a Covered Employee’s Award Agreement, the Committee shall have the discretion, on the basis of such criteria as may be established by the
Committee, to reduce some or all of the value of the Performance Award that would otherwise be paid to the Covered Employee upon its settlement notwithstanding the attainment of any Performance Goal and the resulting value of the Performance Award
determined in accordance with the Performance Award Formula. No such reduction may result in an increase in the amount payable upon settlement of another Participant’s Performance Award. 
 (c) Effect of Leaves of Absence. Unless otherwise required by law, payment of the final value, if any, of a Performance Award held by
a Participant who has taken in excess of thirty (30) days in leaves of absence during a Performance Period shall be prorated on the basis of the number of days of the Participant’s Service during the Performance Period during which the
Participant was not on a leave of absence. 
 (d) Notice to Participants. As soon as practicable following the
Committee’s determination and certification in accordance with Sections 9.5(a) and (b), the Company shall notify each Participant of the determination of the Committee. 
 (e) Payment in Settlement of Performance Awards. As soon as practicable following the Committee’s determination and certification
in accordance with Sections 9.5(a) and (b), payment shall be made to each eligible Participant (or such Participant’s legal representative or other person who acquired the right to receive such payment by reason of the Participant’s
death) of the final value of the Participant’s Performance Award. Payment of such amount shall be made in cash, shares of Stock, or a combination thereof as determined by the Committee. Unless otherwise provided in the Award Agreement
evidencing a Performance Award, payment shall be made in a lump sum. An Award Agreement may provide for deferred payment in a lump sum or in installments. If any payment is to be made on a deferred basis, the Committee may, but shall not be
obligated to, provide for the payment during the deferral period of Dividend Equivalents or interest. 
 (f) Provisions Applicable to
Payment in Shares. If payment is to be made in shares of Stock, the number of such shares shall be determined by dividing the final value of the Performance Award by the value of a share of Stock determined by the method specified in
the Award Agreement. Such methods may include, without limitation, the closing market price on a specified date (such as the settlement date) or an average of market prices over a series of trading days. Shares of Stock issued in payment of any
Performance Award may be fully vested and freely transferable shares or may be shares of Stock subject to Vesting Conditions as provided in Section 8.5. Any shares subject to Vesting Conditions shall be evidenced by an appropriate Award
Agreement and shall be subject to the provisions of Sections 8.5 through 8.8 above. 
  

 A-15 

 9.6 Voting Rights; Dividend Equivalent Rights and Distributions. Participants shall have no
voting rights with respect to shares of Stock represented by Performance Share Awards until the date of the issuance of such shares, if any (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of
the Company). However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Performance Share Award that the Participant shall be entitled to receive Dividend Equivalents with respect to the payment of cash dividends
on Stock having a record date prior to the date on which the Performance Shares are settled or forfeited. Such Dividend Equivalents, if any, shall be credited to the Participant in the form of additional whole Performance Shares as of the date of
payment of such cash dividends on Stock. The number of additional Performance Shares (rounded to the nearest whole number) to be so credited shall be determined by dividing (a) the amount of cash dividends paid on such date with respect to the
number of shares of Stock represented by the Performance Shares previously credited to the Participant by (b) the Fair Market Value per share of Stock on such date. Dividend Equivalents may be paid currently or may be accumulated and paid to
the extent that Performance Shares become nonforfeitable, as determined by the Committee. Settlement of Dividend Equivalents may be made in cash, shares of Stock, or a combination thereof as determined by the Committee, and may be paid on the same
basis as settlement of the related Performance Share as provided in Section 9.5. Dividend Equivalents shall not be paid with respect to Performance Units. In the event of a dividend or distribution paid in shares of Stock or any other
adjustment made upon a change in the capital structure of the Company as described in Section 4.2, appropriate adjustments shall be made in the Participant’s Performance Share Award so that it represents the right to receive upon
settlement any and all new, substituted or additional securities or other property (other than normal cash dividends) to which the Participant would entitled by reason of the shares of Stock issuable upon settlement of the Performance Share Award,
and all such new, substituted or additional securities or other property shall be immediately subject to the same Performance Goals as are applicable to the Award. 
 9.7 Effect of Termination of Service. The effect of a Participant’s termination of Service on the Performance Award shall be determined by the Committee, in its discretion, and set forth in the Award
Agreement evidencing such Performance Award. 
 9.8 Nontransferability of Performance Awards. Prior to settlement in accordance
with the provisions of the Plan, no Performance Award shall be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant’s
beneficiary, except transfer by will or by the laws of descent and distribution. All rights with respect to a Performance Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the
Participant’s guardian or legal representative. 
  

	10.	TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT
AWARDS. 

 Restricted Stock Unit Awards shall be evidenced by Award Agreements specifying the number of
Restricted Stock Units subject to the Award, in such form as the Committee shall from time to time establish. No Restricted Stock Unit Award or purported Restricted Stock Unit Award shall be a valid and binding obligation of the Company unless
evidenced by a fully executed Award Agreement. Award Agreements evidencing Restricted Stock Units may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions:

 10.1 Grant of Restricted Stock Unit Awards. Restricted Stock Unit Awards may be granted upon such conditions as the Committee
shall determine, including, without limitation, upon the attainment of one or more Performance Goals described in Section 9.4. If either the grant of a Restricted Stock Unit Award or the Vesting Conditions with respect to such Award is to be
contingent upon the attainment of one or more Performance Goals, the Committee shall follow procedures substantially equivalent to those set forth in Sections 9.3 through 9.5(a). 
 10.2 Purchase Price. No monetary payment (other than applicable tax withholding, if any) shall be required as a condition of receiving a
Restricted Stock Unit Award, the consideration for which shall be services actually rendered to a Participating Company or for its benefit. 
  

 A-16 

 10.3 Vesting. Restricted Stock Units may or may not be made subject to Vesting Conditions
based upon the satisfaction of such Service requirements, conditions, restrictions or performance criteria, including, without limitation, Performance Goals as described in Section 9.4, as shall be established by the Committee and set forth in
the Award Agreement evidencing such Award. 
 10.4 Voting Rights, Dividend Equivalent Rights and Distributions. Participants
shall have no voting rights with respect to shares of Stock represented by Restricted Stock Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent
of the Company). However, the Committee, in its discretion, may provide in the Award Agreement evidencing any Restricted Stock Unit Award that the Participant shall be entitled to receive Dividend Equivalents with respect to the payment of cash
dividends on Stock having a record date prior to date on which Restricted Stock Units held by such Participant are settled. Such Dividend Equivalents, if any, shall be paid by crediting the Participant with additional whole Restricted Stock Units as
of the date of payment of such cash dividends on Stock. The number of additional Restricted Stock Units (rounded to the nearest whole number) to be so credited shall be determined by dividing (a) the amount of cash dividends paid on such date
with respect to the number of shares of Stock represented by the Restricted Stock Units previously credited to the Participant by (b) the Fair Market Value per share of Stock on such date. Such additional Restricted Stock Units shall be subject
to the same terms and conditions and shall be settled in the same manner and at the same time (or as soon thereafter as practicable) as the Restricted Stock Units originally subject to the Restricted Stock Unit Award. In the event of a dividend or
distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of the Company as described in Section 4.2, appropriate adjustments shall be made in the Participant’s Restricted Stock Unit Award so
that it represents the right to receive upon settlement any and all new, substituted or additional securities or other property (other than normal cash dividends) to which the Participant would entitled by reason of the shares of Stock issuable upon
settlement of the Award, and all such new, substituted or additional securities or other property shall be immediately subject to the same Vesting Conditions as are applicable to the Award. 
 10.5 Effect of Termination of Service. Unless otherwise provided by the Committee in the grant of a Restricted Stock Unit Award and set forth
in the Award Agreement, if a Participant’s Service terminates for any reason, whether voluntary or involuntary (including the Participant’s death or Disability), then the Participant shall forfeit to the Company any Restricted Stock Units
pursuant to the Award which remain subject to Vesting Conditions as of the date of the Participant’s termination of Service. 
 10.6
Settlement of Restricted Stock Unit Awards. The Company shall issue to a Participant on the date on which Restricted Stock Units subject to the Participant’s Restricted Stock Unit Award vest or on such other date determined by the
Committee, in its discretion, and set forth in the Award Agreement one (1) share of Stock (and/or any other new, substituted or additional securities or other property pursuant to an adjustment described in Section 10.4) for each
Restricted Stock Unit then becoming vested or otherwise to be settled on such date, subject to the withholding of applicable taxes. Notwithstanding the foregoing, if permitted by the Committee and set forth in the Award Agreement, the Participant
may elect in accordance with terms specified in the Award Agreement to defer receipt of all or any portion of the shares of Stock or other property otherwise issuable to the Participant pursuant to this Section. 
 10.7 Nontransferability of Restricted Stock Unit Awards. Prior to the issuance of shares of Stock in settlement of a Restricted Stock Unit
Award, the Award shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant’s beneficiary, except transfer by will
or by the laws of descent and distribution. All rights with respect to a Restricted Stock Unit Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the Participant’s guardian or
legal representative. 
  

 A-17 

	11.	DEFERRED STOCK UNITS. 

 11.1 Establishment of Deferred Stock Unit Program. The Committee, in its discretion and upon such terms and conditions as it may determine, may establish one or more programs pursuant to the Plan under
which: 
 (a) Participants designated by the Committee who are Insiders or otherwise among a select group of highly compensated Employees may
irrevocably elect, prior to a date specified by the Committee, to reduce such Participant’s compensation otherwise payable in cash (subject to any minimum or maximum reductions imposed by the Committee) and to be granted automatically at such
time or times as specified by the Committee one or more Awards of Deferred Stock Units with respect to such numbers of shares of Stock as determined in accordance with the rules of the program established by the Committee and having such other terms
and conditions as established by the Committee. 
 (b) Participants designated by the Committee who are Insiders or otherwise among a select
group of highly compensated Employees may irrevocably elect, prior to a date specified by the Committee, to be granted automatically an Award of Deferred Stock Units with respect to such number of shares of Stock and upon such other terms and
conditions as established by the Committee in lieu of: 
 (i) shares of Stock otherwise issuable to such Participant upon the exercise of an
Option; 
 (ii) cash or shares of Stock otherwise issuable to such Participant upon the exercise of a SAR; or 
 (iii) cash or shares of Stock otherwise issuable to such Participant upon the settlement of a Performance Award. 
 11.2 Terms and Conditions of Deferred Stock Units. Deferred Stock Units granted pursuant to this Section 11 shall be evidenced by Award
Agreements in such form as the Committee shall from time to time establish. No such Deferred Stock Unit or purported Deferred Stock Unit shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement.
Award Agreements evidencing Deferred Stock Units may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: 
 (a) Vesting Conditions. Deferred Stock Units shall not be subject to any vesting conditions. 
 (b) Terms and Conditions of Deferred Stock Units. 
 (i) Voting Rights; Dividend Equivalent Rights and Distributions. Participants shall have no voting rights with respect to shares of Stock represented by Deferred Stock Units until the date of the issuance
of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). However, a Participant shall be entitled to receive Dividend Equivalents with respect to the payment of cash
dividends on Stock having a record date prior to date on which Deferred Stock Units held by such Participant are settled. Such Dividend Equivalents shall be paid by crediting the Participant with additional whole and/or fractional Deferred Stock
Units as of the date of payment of such cash dividends on Stock. The method of determining the number of additional Deferred Stock Units to be so credited shall be specified by the Committee and set forth in the Award Agreement. Such additional
Deferred Stock Units shall be subject to the same terms and conditions and shall be settled in the same manner and at the same time (or as soon thereafter as practicable) as the Deferred Stock Units originally subject to the Deferred Stock Unit
Award. In the event of a dividend or distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of the Company as described in Section 4.2, appropriate adjustments shall be made in the
Participant’s Deferred Stock Unit Award so that it represent the right to receive upon settlement any and all new, substituted or additional securities or other property (other than normal cash dividends) to which the Participant would entitled
by reason of the shares of Stock issuable upon settlement of the Award. 
 (ii) Settlement of Deferred Stock Unit Awards. A
Participant electing to receive an Award of Deferred Stock Units pursuant to this Section 11, shall specify at the time of such election a settlement date with respect to such Award. The Company shall issue to the Participant as soon as
practicable 
  

 A-18 

 following the earlier of the settlement date elected by the Participant or the date of termination of the
Participant’s Service, a number of whole shares of Stock equal to the number of whole Deferred Stock Units subject to the Deferred Stock Unit Award. Such shares of Stock shall be fully vested, and the Participant shall not be required to pay
any additional consideration (other than applicable tax withholding) to acquire such shares. Any fractional Deferred Stock Unit subject to the Deferred Stock Unit Award shall be settled by the Company by payment in cash of an amount equal to the
Fair Market Value as of the payment date of such fractional share. 
 (iii) Nontransferability of Deferred Stock Unit
Awards. Prior to their settlement in accordance with the provision of the Plan, no Deferred Stock Unit Award shall be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or
garnishment by creditors of the Participant or the Participant’s beneficiary, except transfer by will or by the laws of descent and distribution. All rights with respect to a Deferred Stock Unit Award granted to a Participant hereunder shall be
exercisable during his or her lifetime only by such Participant or the Participant’s guardian or legal representative. 
  

	12.	STANDARD FORMS OF AWARD AGREEMENT. 

 12.1 Award Agreements. Each Award shall comply with and be subject to the terms and conditions set forth in the appropriate form
of Award Agreement approved by the Committee and as amended from time to time. Any Award Agreement may consist of an appropriate form of Notice of Grant and a form of Agreement incorporated therein by reference, or such other form or forms as the
Committee may approve from time to time. 
 12.2 Authority to Vary Terms. The Committee shall have the authority
from time to time to vary the terms of any standard form of Award Agreement either in connection with the grant or amendment of an individual Award or in connection with the authorization of a new standard form or forms; provided, however, that the
terms and conditions of any such new, revised or amended standard form or forms of Award Agreement are not inconsistent with the terms of the Plan. 
  

	13.	CHANGE IN CONTROL. 

 13.1 Definitions. 
 (a) An “Ownership Change Event” shall be
deemed to have occurred if any of the following occurs with respect to the Company: (i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent
(50%) of the voting stock of the Company; (ii) a merger or consolidation in which the Company is a party; (iii) the sale, exchange, or transfer of all or substantially all of the assets of the Company (other than a sale, exchange or
transfer to one or more subsidiaries of the Company); or (iv) a liquidation or dissolution of the Company. 
 (b) A
“Change in Control” shall mean an Ownership Change Event or series of related Ownership Change Events (collectively, a “Transaction”) in which the stockholders of the Company
immediately before the Transaction do not retain immediately after the Transaction, in substantially the same proportions as their ownership of shares of the Company’s voting stock immediately before the Transaction, direct or indirect
beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding voting securities of the Company or, in the case of an Ownership Change Event described in Section 13.1(a)(iii), the entity to
which the assets of the Company were transferred (the “Transferee”), as the case may be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest
resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business
entities. The Committee shall have the right to determine whether multiple sales or exchanges of the voting securities of the Company or multiple Ownership Change Events are related, and its determination shall be final, binding and conclusive.

  

 A-19 

 13.2 Effect of Change in Control on Options and SARs. 
 (a) Accelerated Vesting. Notwithstanding any other provision of the Plan to the contrary, the Committee, in its sole discretion, may
provide in any Award Agreement or, in the event of a Change in Control, may take such actions as it deems appropriate to provide for the acceleration of the exercisability and vesting in connection with such Change in Control of any or all
outstanding Options and SARs and shares acquired upon the exercise of such Options and SARs upon such conditions and to such extent as the Committee shall determine. 
 (b) Assumption or Substitution. In the event of a Change in Control, the surviving, continuing, successor, or purchasing corporation or other business entity or parent corporation thereof, as the
case may be (the “ Acquiring Corporation “ ), may, without the consent of the Participant, either assume the Company’s rights and obligations under outstanding Options and SARs or substitute for outstanding
Options and SARs substantially equivalent options and stock appreciation rights for the Acquiring Corporation’s stock. In the event that the Acquiring Corporation elects not to assume or substitute for outstanding Options and SARs in connection
with a Change in Control, or if the Acquiring Corporation is not a “publicly held corporation” within the meaning of Section 162(m), the exercisability and vesting of each such outstanding Option, SAR and any shares acquired upon the
exercise thereof held by a Participant whose Service has not terminated prior to such date shall be accelerated, effective as of the date ten (10) days prior to the date of the Change in Control. The exercise or vesting of any Option, SAR and
any shares acquired upon the exercise thereof that was permissible solely by reason of this Section 13.2 and the provisions of such applicable Award Agreement shall be conditioned upon the consummation of the Change in Control. Any Options and
SARs which are neither assumed or substituted for by the Acquiring Corporation in connection with the Change in Control nor exercised as of the date of the Change in Control shall terminate and cease to be outstanding effective as of the date of the
Change in Control. Notwithstanding the foregoing, shares acquired upon exercise of an Option or SAR prior to the Change in Control and any consideration received pursuant to the Change in Control with respect to such shares shall continue to be
subject to all applicable provisions of the applicable Award Agreement evidencing such Option or SAR except as otherwise provided in such applicable Award Agreement. Furthermore, notwithstanding the foregoing, if the corporation the stock of which
is subject to the outstanding Options and SARs immediately prior to an Ownership Change Event described in Section 13.1(a)(i) constituting a Change in Control is the surviving or continuing corporation and immediately after such Ownership
Change Event less than fifty percent (50%) of the total combined voting power of its voting stock is held by another corporation or by other corporations that are members of an affiliated group within the meaning of Section 1504(a) of the
Code without regard to the provisions of Section 1504(b) of the Code, the outstanding Options and SARs shall not terminate unless the Committee otherwise provides in its discretion. 
 (c) Cash-Out. The Committee may, in its sole discretion and without the consent of any Participant, determine that, upon the
occurrence of a Change in Control, each or any Option or SAR outstanding immediately prior to the Change in Control shall be canceled in exchange for a payment with respect to each vested share of Stock subject to such canceled Option or SAR in
(i) cash, (ii) stock of the Company or of a corporation or other business entity a party to the Change in Control, or (iii) other property which, in any such case, shall be in an amount having a Fair Market Value equal to the excess
of the Fair Market Value of the consideration to be paid per share of Stock in the Change in Control over the exercise price per share under such Option or SAR (the “ Spread “ ). In the event such determination
is made by the Committee, the Spread (reduced by applicable withholding taxes, if any) shall be paid to Participants in respect of their canceled Options and SARs as soon as practicable following the date of the Change in Control. 
 13.3 Effect of Change in Control on Restricted Stock Awards. The Committee may, in its discretion, provide in any Award Agreement evidencing
a Restricted Stock Award that, in the event of a Change in Control, the lapsing of the Restriction Period applicable to the shares subject to the Restricted Stock Award held by a Participant whose Service has not terminated prior to the Change in
Control shall be accelerated effective immediately prior to the consummation of the Change in Control to such extent as specified in such Award 
  

 A-20 

 Agreement. Any acceleration of the lapsing of the Restriction Period that was permissible solely by reason of this
Section 13.3 and the provisions of such Award Agreement shall be conditioned upon the consummation of the Change in Control. 
 13.4
Effect of Change in Control on Performance Awards. The Committee may, in its discretion, provide in any Award Agreement evidencing a Performance Award that, in the event of a Change in Control, the Performance Award held by a Participant
whose Service has not terminated prior to the Change in Control shall become payable effective as of the date of the Change in Control to such extent as specified in such Award Agreement. 
 13.5 Effect of Change in Control on Restricted Stock Unit Awards. The Committee may, in its discretion, provide in any Award Agreement
evidencing a Restricted Stock Unit Award that, in the event of a Change in Control, the Restricted Stock Unit Award held by a Participant whose Service has not terminated prior to such date shall be settled effective as of the date of the Change in
Control to such extent as specified in such Award Agreement. 
 13.6 Effect of Change in Control on Deferred Stock Units. The
Committee may, in its discretion, provide in any Award Agreement evidencing a Deferred Stock Unit Award that, in the event of a Change in Control, the Deferred Stock Units pursuant to such Award shall be settled effective as of the date of the
Change in Control to such extent as specified in such Award Agreement. 
  

	14.	COMPLIANCE WITH SECURITIES LAW. 

 The grant
of Awards and the issuance of shares of Stock pursuant to any Award shall be subject to compliance with all applicable requirements of federal, state and foreign law with respect to such securities and the requirements of any stock exchange or
market system upon which the Stock may then be listed. In addition, no Award may be exercised or shares issued pursuant to an Award unless (a) a registration statement under the Securities Act shall at the time of such exercise or issuance be
in effect with respect to the shares issuable pursuant to the Award or (b) in the opinion of legal counsel to the Company, the shares issuable pursuant to the Award may be issued in accordance with the terms of an applicable exemption from the
registration requirements of the Securities Act. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company’s legal counsel to be necessary to the lawful issuance and sale of
any shares hereunder shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority shall not have been obtained. As a condition to issuance of any Stock, the Company may
require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the
Company. 
  

	15.	TAX WITHHOLDING. 

 15.1 Tax Withholding in
General. The Company shall have the right to deduct from any and all payments made under the Plan, or to require the Participant, through payroll withholding, cash payment or otherwise, including by means of a Cashless Exercise of an
Option, to make adequate provision for, the federal, state, local and foreign taxes, if any, required by law to be withheld by the Participating Company Group with respect to an Award or the shares acquired pursuant thereto. The Company shall have
no obligation to deliver shares of Stock, to release shares of Stock from an escrow established pursuant to an Award Agreement, or to make any payment in cash under the Plan until the Participating Company Group’s tax withholding obligations
have been satisfied by the Participant. 
 15.2 Withholding in Shares. The Company shall have the right, but not the obligation,
to deduct from the shares of Stock issuable to a Participant upon the exercise or settlement of an Award, or to accept from the Participant the tender of, a number of whole shares of Stock having a Fair Market Value, as determined by the 

 

 A-21 

 Company, equal to all or any part of the tax withholding obligations of the Participating Company Group. The Fair Market
Value of any shares of Stock withheld or tendered to satisfy any such tax withholding obligations shall not exceed the amount determined by the applicable minimum statutory withholding rates. 
  

	16.	AMENDMENT OR TERMINATION OF PLAN. 

 The Committee may amend, suspend or terminate the Plan at any time. However, without the approval of the Company’s stockholders, there shall be
(a) no increase in the maximum aggregate number of shares of Stock that may be issued under the Plan (except by operation of the provisions of Section 4.2), (b) no change in the class of persons eligible to receive Incentive Stock
Options, (c) no Option and/or SAR repricing as described in Section 3.6, (d) no amendment to permit the granting of Options (other than Indexed Options) with exercise prices less than Fair Market Value on the date of grant, and
(e) no other amendment of the Plan that would require approval of the Company’s stockholders under any applicable law, regulation or rule. No amendment, suspension or termination of the Plan shall affect any then outstanding Award unless
expressly provided by the Committee. In any event, no amendment, suspension or termination of the Plan may adversely affect any then outstanding Award without the consent of the Participant unless necessary to comply with any applicable law,
regulation or rule. 
  

	17.	MISCELLANEOUS PROVISIONS. 

 17.1 Repurchase Rights. Shares issued under the Plan may be subject to one or more repurchase options, or other conditions and restrictions as determined by the Committee in its discretion at
the time the Award is granted. The Company shall have the right to assign at any time any repurchase right it may have, whether or not such right is then exercisable, to one or more persons as may be selected by the Company. Upon request by the
Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares of Stock hereunder and shall promptly present to the Company any and all certificates representing shares of Stock acquired
hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions. 
 17.2 Provision of
Information. Each Participant shall be given access to information concerning the Company equivalent to that information generally made available to the Company’s common stockholders. 
 17.3 Rights as Employee, Consultant or Director. No person, even though eligible pursuant to Section 5, shall have a right to be
selected as a Participant, or, having been so selected, to be selected again as a Participant. Nothing in the Plan or any Award granted under the Plan shall confer on any Participant a right to remain an Employee, Consultant or Director or interfere
with or limit in any way any right of a Participating Company to terminate the Participant’s Service at any time. To the extent that an Employee of a Participating Company other than the Company receives an Award under the Plan, that Award
shall in no event be understood or interpreted to mean that the Company is the Employee’s employer or that the Employee has an employment relationship with the Company. 
 17.4 Rights as a Stockholder. A Participant shall have no rights as a stockholder with respect to any shares covered by an Award until the
date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment shall be made for dividends, distributions or other rights for which the
record date is prior to the date such shares are issued, except as provided in Section 4.2 or another provision of the Plan. 
 17.5
Fractional Shares. The Company shall not be required to issue fractional shares upon the exercise or settlement of any Award. 
 17.6 Severability. If any one or more of the provisions (or any part thereof) of this Plan or of any Award Agreement issued hereunder, shall be held to be invalid, illegal or unenforceable in any respect, such provision shall be
modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the 
  

 A-22 

 remaining provisions (or any part thereof) of the Plan or of any Award Agreement shall not in any way be affected or
impaired thereby. The Company may, without the consent of any Participant, and in a manner determined necessary solely in the discretion of the Company, amend the Plan and any outstanding Award Agreement as the Company deems necessary to ensure the
Plan and all Awards remain valid, legal or enforceable in all respects. 
 17.7 Beneficiary Designation. Subject to local laws
and procedures, each Participant may file with the Company a written designation of a beneficiary who is to receive any benefit under the Plan to which the Participant is entitled in the event of such Participant’s death before he or she
receives any or all of such benefit. Each designation will revoke all prior designations by the same Participant, shall be in a form prescribed by the Company, and will be effective only when filed by the Participant in writing with the Company
during the Participant’s lifetime. If a married Participant designates a beneficiary other than the Participant’s spouse, the effectiveness of such designation may be subject to the consent of the Participant’s spouse. If a
Participant dies without an effective designation of a beneficiary who is living at the time of the Participant’s death, the Company will pay any remaining unpaid benefits to the Participant’s legal representative. 
 17.8 Unfunded Obligation. Participants shall have the status of general unsecured creditors of the Company. Any amounts payable to
Participants pursuant to the Plan shall be unfunded and unsecured obligations for all purposes, including, without limitation, Title I of the Employee Retirement Income Security Act of 1974. No Participating Company shall be required to
segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations. The Company shall retain at all times beneficial ownership of any investments, including trust investments,
which the Company may make to fulfill its payment obligations hereunder. Any investments or the creation or maintenance of any trust or any Participant account shall not create or constitute a trust or fiduciary relationship between the Committee or
any Participating Company and a Participant, or otherwise create any vested or beneficial interest in any Participant or the Participant’s creditors in any assets of any Participating Company. The Participants shall have no claim against any
Participating Company for any changes in the value of any assets which may be invested or reinvested by the Company with respect to the Plan. 
  

 A-23Drug Product Development and Clinical Supply Agreement

 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
 EXHIBIT 10.58 
 Drug Product Development and Clinical Supply Agreement 
 THIS DRUG PRODUCT DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (the “Agreement”) is effective as of the 28th day of April 2006 (the
“Effective Date”). 
 BY AND BETWEEN: 
 NUVELO, INC., a corporation organized and existing under the laws of the state of Delaware, with its principal offices located at 201 Industrial Road, Suite 310, San Carlos, CA 94070 (hereinafter referred to as
“NUVELO”); 
 AND: 
 BAXTER
PHARMACEUTICAL SOLUTIONS LLC, a Delaware limited liability company, with a place of business located at 927 South Curry Pike in Bloomington, Indiana 47403 (hereinafter referred to as “BPS”); 
 WHEREAS, NUVELO has rights to patents, formulations and know-how related to each Drug Product, as defined below; 
 WHEREAS, BPS has the expertise and the manufacturing facility suitable for the Production (as defined below) and Development (as defined below) of Drug Product;

 WHEREAS, NUVELO wishes to have BPS Produce and Develop Drug Product and BPS wishes to Produce and Develop Drug Product for NUVELO; 
 NOW, THEREFORE, in consideration of the premises and the undertakings, terms, conditions and covenants set forth below, the Parties hereto agree as follows:

 Article 1, DEFINITIONS. 
  

	 	1.1	AFFILIATE of a Party hereto shall mean any entity that controls or is controlled by such Party, or is under common control with such Party. For purposes of this definition,
an entity shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the voting equity of another entity. 

  

	 	1.2	BLA shall mean the FDA required Biologics License Application, or the equivalent thereof in any other jurisdiction. 

  

	 	1.3	APPLICABLE LAWS shall mean all applicable supranational, national or local laws, rules and regulations of the United States and the European Union that apply to the
production of pharmaceutical products, including without limitation 

  

					
	NUVELO	 	Page 1 of 36	 	CONFIDENTIAL

 the sections of the FD&C Act relating to biologics manufacture, as amended from time to time, the
regulations promulgated pursuant thereto, and any successor laws, rules or regulations of any of the preceding. A law that applies specifically to the Production of Drug Product, and not generally to the production of pharmaceutical products, does
not become an Applicable Law under this Agreement until it is disclosed in written or Electronic form to BPS by NUVELO. 
  

	 	1.4	BATCH shall mean a specific quantity of a Drug Product, comprising a number of units mutually agreed upon between NUVELO and BPS, that (a) is intended to have uniform
character and quality within specified limits, and (b) is Produced according to a single manufacturing order during the same cycle of manufacture. 

  

	 	1.5	BATCH PURCHASE PRICE (BPP) shall mean the fees and costs charged for the Production of a specific Batch, as expressly set forth in the applicable Project Plan.

  

	 	1.6	BILL of MATERIALS shall mean a bill of materials which sets forth in detail the specific components, materials and excipients necessary for performance under a particular
Plan or set of specifically-related Plans. Each Bill of Materials will be generated electronically by BPS and transmitted electronically to NUVELO. NUVELO shall review, approve and execute, or modify, the applicable Bill of Materials. If NUVELO
modifies the Bill of Materials, the Parties will promptly commence discussions on the components, materials and excipients to be set forth in the Bill of Materials. Once the Parties have reached agreement on the content of the Bill of Materials and
a new Bill of Materials has been generated and transmitted electronically to NUVELO by BPS, NUVELO shall return one (1) executed copy of the final version of the Bill of Materials to BPS. BPS is bound by any Bill of Materials electronically
submitted to Nuvelo that NUVELO executes without modifying its terms. 

  

	 	1.7	BPS SOPs shall mean BPS’ standard operating procedures, which do not include the DPS SOPs. Copies of BPS SOPs will be made available to NUVELO for auditing purposes in
accordance with Section 5.8. BPS SOPs shall be deemed approved by NUVELO [        *        ], but deemed approval of BPS SOPs does not, nor shall it be
deemed to result in, approval of any DPS SOP or any MBR in which any BPS SOP is referenced. 

  

	 	1.8	BULK DRUG SUBSTANCE (BDS) shall mean the active compound, alfimeprase, as set forth in the Development Plan and/or Project Plan, to be supplied by NUVELO for use in
Production or Development of Drug Product. 

  

	 	1.9	cGMP shall mean current Good Manufacturing Practices as defined and established in 21 CFR Parts 210-211 and in Eudralex - Volume 4 - Medicinal Products for Human and
Veterinary Use - Good Manufacturing Practice, and any successor laws, rules or regulations of any of the preceding. 

  

	 	1.10	CANCELLATION FEES shall mean the fees set forth in Section 3.4. 

 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as
amended. 
  

					
	NUVELO	 	Page 2 of 36	 	CONFIDENTIAL

	 	1.11	CERTIFICATE OF ANALYSIS shall mean a section of the QCMD containing a compilation of the analytical tests methods applied, specifications for each test and test results for a
particular Batch of Drug Product. 

  

	 	1.12	COMPONENTS shall mean all components, including without limitation vials, stoppers, seals, raw materials and excipients, used by BPS in Production of Drug Product under this
Agreement, including components provided by BPS and components provided by NUVELO, but specifically excluding Capital Equipment. All Components are identified as either components supplied by NUVELO (the “NUVELO Supplied
Components”) or components supplied by BPS (the “BPS Supplied Components”). All BPS Supplied Components necessary for the performance of a particular Plan are listed in the Bill of Materials applicable to that particular
Plan. All NUVELO Supplied Components applicable to a particular Plan are set forth in the applicable Plan. Any and all NUVELO Supplied Components that need to be stored in an environmentally-controlled location to avoid loss or damage are referred
to herein as “NUVELO EC Components”. 

  

	 	1.13	CONFIDENTIAL INFORMATION shall mean all Information disclosed by one Party (the “Disclosing Party”), its officers, directors, employees, consultants,
contractors or agents and those of its Affiliates to the other Party (the “Receiving Party”) that is marked “Confidential” at the time of disclosure if disclosed in written or tangible form; or is disclosed orally or
disclosed by visual observation during a tour, site visit, or audit of either Party or any of their Affiliates’ laboratories, manufacturing plants or other facilities. Notwithstanding the preceding, if a Party fails to mark written or tangibly
disclosed Information as “Confidential,” but notifies the other Party in writing of the confidential nature of the Information within ten (10) business days after the date of disclosure, the Information shall become “Confidential
Information” as set forth herein. Confidential Information shall not include Information which: (i) is known to the Receiving Party as evidenced by its written records before receipt thereof from the Disclosing Party; (ii) is
disclosed to the Receiving Party by a third person who has the right to make such disclosure; (iii) is or becomes part of the public domain through no breach of this Agreement by the Receiving Party; or (iv) the recipient can reasonably
establish by competent evidence is independently developed by an employee, consultant or agent of the Receiving Party without reference to or use of the Confidential Information disclosed by the Disclosing Party. 

  

	 	1.14	DEVELOPMENT shall mean studies conducted by BPS to develop a process to Produce Drug Product, in accordance with the Specifications, cGMP and Applicable Laws. Development
activities agreed upon by the Parties shall be expressly set forth in a Development Plan. 

  

	 	1.15	DEVELOPMENT PLAN shall mean a document containing the parameters for the Development of Drug Product which shall be developed by BPS in conjunction with NUVELO and agreed to
in writing by the Parties for each Drug Product under this Agreement. 

  

					
	NUVELO	 	Page 3 of 36	 	CONFIDENTIAL

	 	1.16	DELIVERABLES shall mean: (a) all Drug Product, all unused BDS and NUVELO Components (“Material Deliverables”); and (b) any and all information,
data, materials, reports and documentation to be delivered to NUVELO by BPS in accordance with an applicable Plan, this Agreement or the Quality Agreement (“Information Deliverables”), except that Information Deliverables shall not
include [        *        ], any [        *        ] or
[         *        ] or [        *        ], or the formatting of any documentation
generated by BPS, [        *        ] or [        *        ] information, data,
materials, reports or documentation provided to NUVELO by BPS in accordance with an applicable Plan, this Agreement or the Quality Agreement. 

  

	 	1.17	DOCUMENT REVIEW PERIOD has the meaning assigned to it in Section 6.1. 

  

	 	1.18	DRUG PRODUCT shall mean pharmaceutical product (or placebo, if applicable) Developed or Produced by BPS in final liquid or lyophilized dosage form, capped, packaged and
labeled for shipment for development and/or clinical use only, as specified in this Agreement and the applicable Plan. 

  

	 	1.19	DRUG PRODUCT SPECIFIC SOPs (DPS SOPs) shall mean standard operating procedures that are specific to the Production of Drug Product. DPS SOPs shall be approved by both Parties
by prior written or prior Electronically-documented approval. 

  

	 	1.20	ELECTRONIC or ELECTRONICALLY shall mean e-mail transmission, receipt of the transmission confirmed by e-mail return receipt; or facsimile transmission, receipt of the
transmission confirmed by fax transmittal confirmation page. 

  

	 	1.21	EXPOSURE EVENT shall have the meaning set forth in the Quality Agreement. 

  

	 	1.22	FDA shall mean the United States Food and Drug Administration or any successor entity thereto. 

  

	 	1.23	FD&C ACT shall mean the United States Federal Food, Drug and Cosmetic Act, as may be amended from time to time. 

  

	 	1.24	FINAL RELEASE shall mean NUVELO’s acceptance of the Release Documentation provided to NUVELO by BPS for a particular Batch of Drug Product, which acceptance shall be set
forth in a written notice to BPS. “Finally Released” shall mean and refer to a Batch for which Release Documentation has been accepted by NUVELO. 

  

	 	1.25	INFORMATION shall mean any and all scientific, technical, trade, financial, personnel or business information, whether tangible or intangible and whether or not patentable or
copyrightable, including without limitation: a) inventions, discoveries, methods, know-how, processes, code, data, formulations or diagrams; b) amino acid or nucleic acid sequences, expression systems, cells, cell lines, 

 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 4 of 36	 	CONFIDENTIAL

 organisms, antibodies, biological substances, and any constituents, progeny, mutants, derivatives or
replications of them or from them, together with all reagents, chemical compounds or other material; and c) information regarding equipment or apparatus, software, clinical or regulatory reports and filings, patent prosecution status and strategy,
business plans or research, financial, employment, operational or marketing developments. 
  

	 	1.26	INVENTION has the meaning assigned to it in Section 11.2. 

  

	 	1.27	LABELING shall mean all labels and other written, printed, or graphic matter upon: (i) Drug Product or any container, carton, or wrapper utilized with Drug Product; or
(ii) any written material accompanying Drug Product. 

  

	 	1.28	MASTER BATCH RECORD (MBR) shall mean the formal set of instructions setting forth the procedure to be followed for the Production of Drug Product, including but not limited
to the history of a Batch from the raw material stage up through and until completion of the Batch, a complete list of all active and inactive ingredients, components, weights and measures, descriptions of Drug Product containers, closures,
packaging materials, and labeling and complete specifications for each. 

  

	 	1.29	NON-CONFORMITY and NON-CONFORMING have the meaning assigned to each of them in Section 6.1.2. 

  

	 	1.30	PARTY shall mean either NUVELO or BPS, and PARTIES shall mean both NUVELO and BPS. 

  

	 	1.31	PLAN shall mean any Project Plan, Development Plan or Regulatory Plan. 

  

	 	1.32	PRODUCTION or PRODUCE, and any conjugated forms of the preceding, shall mean, as applicable in the applicable Plan, the formulation, lyophilization, filling,
packaging, inspection, labeling, or testing of Drug Product by BPS. 

  

	 	1.33	PRODUCT REQUIREMENTS has the meaning assigned to it in Section 6.1. 

  

	 	1.34	PROJECT PLAN shall mean the document containing the parameters for Production of Drug Product which shall be developed by BPS in conjunction with NUVELO and agreed to in
writing by both Parties for each Drug Product under this Agreement. 

  

	 	1.35	PURCHASE PRICE shall mean the total amount of compensation to be paid by NUVELO to BPS under a particular Plan for, or in support of, Development or Production, as specified
in the applicable Plan. The Purchase Price may consist of a Batch Purchase Price and other fees and costs for services that are not for the Production of a specific Batch, and therefore not part of the Batch Purchase Price. 

 

	 	1.36	QUALITY AGREEMENT shall mean the agreement with that title executed by each of the Parties that allocates responsibilities for quality in relation to Drug Product including,
but not limited to: the quality standards mutually agreed upon in writing applicable for the Production of Drug Product under this Agreement in 

  

					
	NUVELO	 	Page 5 of 36	 	CONFIDENTIAL

 accordance with cGMP and the Release of Drug Product, specifically including the Release Documentation;
and the roles and responsibilities of each Party’s personnel in relation to quality assurance matters under this Agreement. 
  

	 	1.37	QUALITY CONTROL MASTER DOCUMENT (QCMD) shall mean a document, agreed upon in writing or prior Electronically-documented approval by the Parties, that lists for each
individual Batch, the analytical testing to be performed on, and corresponding Specifications for, the Bulk Drug Substance, raw materials, consumables and in-process materials and Drug Product, and includes the Certificate of Analysis for the Batch.

  

	 	1.38	REGULATORY AUTHORITY shall mean those agencies or authorities responsible for regulation of Drug Product in the United States, the European Union and in the other territories
of the world. BPS shall have no obligation to Produce Drug Product in compliance with the requirements of a Regulatory Authority, [        *        ], unless the
Regulatory Authority is specified in the applicable Plan. Each Plan generated by BPS under this Agreement and delivered to NUVELO is required to include a list of Regulatory Authorities,
[        *        ] NUVELO may, in its sole discretion, agree to limit the Regulatory Authorities applicable to a particular Plan by agreeing to an express statement in
the applicable Plan that [        *        ] are not applicable to Production under the applicable Plan. 

  

	 	1.39	REGULATORY PLAN shall mean a document containing regulatory services and support for the development and maintenance of regulatory submissions and supporting documentation
mutually developed by the Parties and agreed to in writing by the Parties. 

  

	 	1.40	RELEASE, or with correlative meaning, RELEASED, shall mean the process by which, in respect of each Batch, BPS’ quality assurance team: 

 

	 	1.40.1	reviews and approves completed Batch records; 

  

	 	1.40.2	closes out all exceptions; 

  

	 	1.40.3	issues a QCMD; and 

  

	 	1.40.4	reviews and approves any additional documents as identified in the Quality Agreement. 

  

	 	1.41	RELEASE DOCUMENTATION shall mean the following documentation prepared by BPS and provided to NUVELO by BPS after Release: 

  

	 	1.41.1	Released Executed Batch Record, which includes the QCMD; 

  

	 	1.41.2	Batch-related manufacturing documentation, as set forth in the Quality Agreement; 

 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as
amended. 
  

					
	NUVELO	 	Page 6 of 36	 	CONFIDENTIAL

	 	1.41.3	The QC Batch-related analyses, as set forth in the Quality Agreement; and 

  

	 	1.41.4	Certificate of Analysis (located in the QCMD). 

  

	 	1.42	RELEASED EXECUTED BATCH RECORD shall mean, for each Batch of Drug Product that has been Released: a written record that includes: (i) the completed Batch record, to
include the items set forth in the Quality Agreement, and associated exception reports; (ii) the statement of conformance, if requested by NUVELO pursuant to, or if it is otherwise incorporated into, the relevant MBR; and (iii) the
associated QCMD. 

  

	 	1.43	SPECIFICATIONS shall mean the specifications, including without limitation the specifications for raw materials, consumables, in-process testing and in-process materials:
(i) for Drug Product set forth in the Master Batch Record or QCMD; (ii) for Drug Product provided to BPS by NUVELO and included in the product specification section of the QCMD for a particular Batch; and (iii) to the extent that BPS
is required to test the Bulk Drug Substance (i.e., formulated BDS or sterile-filtered BDS), for the Bulk Drug Substance, as further set forth in the Quality Agreement. 

 Article 2, DEVELOPMENT AND PRODUCTION OF DRUG PRODUCT. 
  

	 	2.1	Initiation: Upon execution of this Agreement and a corresponding Development Plan for each Drug Product, BPS will use good faith, diligent efforts to develop Drug Product
pursuant to the Development Plan for that Drug Product, including any timelines established in that Development Plan. Upon execution of this Agreement and a corresponding Project Plan for each Drug Product, BPS will use good faith, diligent efforts
to Produce Drug Product pursuant to the Project Plan, including any timelines established in that Project Plan. 

  

	 	2.2	Documentation; Plans: 

 2.2.1
Development Plan. Prior to commencing Development hereunder for any Drug Product, BPS shall deliver two (2) signed originals of the mutually developed Development Plan to NUVELO. If NUVELO approves of the Development Plan, NUVELO shall sign
both originals of the Development Plan and return one (1) fully executed original to BPS. Each fully executed Development Plan is incorporated herein by reference and made a part of this Agreement. Neither Party shall have any obligation with
respect to the commencement of Development for a Drug Product until the Parties have executed a Development Plan for such Drug Product. In the event of a conflict between any of the provisions of this Agreement and a Development Plan, the provisions
of this Agreement govern. 
 2.2.2 Project Plan. Prior to commencing Production of any Drug Product, BPS shall deliver
two (2) signed originals of the mutually developed Project Plan to NUVELO. If the Project Plan is acceptable to NUVELO, 
  

					
	NUVELO	 	Page 7 of 36	 	CONFIDENTIAL

 NUVELO shall sign both originals of the Project Plan and return one (1) fully executed original to
BPS. Each fully executed Project Plan is incorporated herein by reference and made a part of this Agreement. Neither Party shall have any obligation with respect to the Production of a Drug Product until both Parties have executed a Project Plan for
such Drag Product. In the event of a conflict between any of the provisions of this Agreement and a Project Plan, the provisions of this Agreement govern. 
 2.2.3 Regulatory Plan. BPS shall execute any mutually agreed upon Regulatory Plan and deliver two (2) originals of the Regulatory Plan to NUVELO. If a Regulatory Plan is acceptable to NUVELO, NUVELO shall
sign both originals of the Regulatory Plan and return one (1) fully executed original to BPS. Upon full execution, the Regulatory Plan is incorporated herein by reference and made a part of this Agreement. Neither Party shall have any
obligation with respect to the performance of regulatory services or the provision of regulatory support for a Drug Product until the Parties have executed a Regulatory Plan in writing for such Drag Product. For the avoidance of doubt, any and all
obligations set forth in the Quality Agreement are not and shall not be deemed to be regulatory services or regulatory support requiring the execution of a Regulatory Plan. In the event of a conflict between any of the provisions of this Agreement
and the Regulatory Plan, the provisions of this Agreement govern. 
 2.2.4 Master Batch Records; Changes to MBRs.
Master Batch Records shall be reviewed and approved by BPS and by NUVELO prior to commencement of Production. The MBR for Drug Product may be amended, supplemented or restated from time to time by mutual written agreement of the Parties. No
changes to the content, specifically including written, graphic, tabular or pictorial content, of an MBR, other than the correction of typographical or formatting errors, or the inclusion of documentation in a Batch-Specific MBR regarding the
occurrence of an exception or deviation from the manufacturing process established in the then-current MBR, as discussed in more detail below, will be made without NUVELO’s prior written or prior Electronically- documented approval. Each Batch
of Drug Product shall be Produced by using a copy of the then-current Master Batch Record. Each copy of the then-current Master Batch Record for a particular Batch of Drag Product (“Batch-Specific MBR”) shall be assigned a
unique Batch number. Any deviation or exception from the manufacturing process specified in the then-current Master Batch Record must be documented in the Batch-Specific MBR. For clarity, BPS’ inclusion of documentation in a Batch-Specific MBR
regarding the occurrence of a deviation or exception from the manufacturing process specified in the then-current MBR is not considered a change to an MBR requiring NUVELO approval as set forth above in this Section 2.2.4; however, any change
to the manufacturing process specified in the then-current MBR that is proposed as a result of the occurrence of the exception or deviation that is documented in the Batch-Specific MBR would be a change requiring both Parties approval, as discussed
above. BPS also shall provide NUVELO with copies of the Released Executed Batch Record for each Batch, as part of the Release Documentation. BPS shall provide NUVELO with 
  

					
	NUVELO	 	Page 8 of 36	 	CONFIDENTIAL

 any required supporting Development and Production documentation in a form reasonably suitable for
NUVELO’s submission to the FDA. 
 2.2.5 Quality Agreement. If the Quality Agreement has not been executed as of
the Effective Date, then once the terms of the Quality Agreement have been mutually agreed upon by the Parties, BPS shall execute the mutually agreed upon Quality Agreement and deliver two (2) originals of the Quality Agreement to NUVELO for
NUVELO’s execution. If the Quality Agreement is acceptable to NUVELO, NUVELO shall sign both originals of the Quality Agreement and return one (1) fully executed original to BPS. Upon full execution, the Quality Agreement is incorporated
herein by reference and made a part of this Agreement. In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement,
[        *        ]. 
 2.2.6 Resources
Necessary for and Amendments to Plans. BPS shall commit the resources and facilities necessary to perform Production and Development in accordance with the terms and conditions of this Agreement and the Plans. The Parties may amend any Plan upon
commercially reasonable terms upon mutual written agreement of the Parties. The Parties recognize that the Parties will need to amend a Plan if NUVELO requires BPS to carry out additional or different work to that specified in the applicable Plan.
Any amendment to a Plan that is mutually agreed upon in writing by the Parties is deemed to be incorporated into, and becomes a part of, the applicable Plan. 
  

	 	2.3	Bulk Drug Substance and Component Supply: NUVELO, at its sole cost and expense (including, without limitation, shipping costs), shall supply to BPS, in the manner and upon
the timeline set forth in the applicable Plan, (a) all Bulk Drug Substance and (b) all other NUVELO Supplied Components. Except as may specifically be set forth otherwise in the applicable Plan or Quality Agreement, on receipt of the Bulk
Drug Substance and NUVELO Supplied Components as set forth above, BPS’ sole obligation with respect to evaluation of the Bulk Drug Substance and NUVELO Supplied Components shall be to review the accompanying Certificate of Analysis to confirm
that the Bulk Drug Substance and any NUVELO Supplied Components conform with the specifications pursuant to BPS’ receiving SOPs. 

  

	 	2.4	Bulk Drug Substance and Component Delivery Delays: BPS shall provide to NUVELO the vendor ordering lead times for all BPS Supplied Components prior to or contemporaneously
with the Bill of Materials. BPS shall have no responsibility for delays in delivery of Drug Product caused by delays in receipt of BPS Supplied Components so long as: (i) BPS has complied with the applicable BPS Supplied Component vendor
ordering lead times; (ii) the vendor ordering lead times have been disclosed to NUVELO prior to or contemporaneously with the Bill of Materials; and (iii) BPS maintains at all times at BPS’ facility, at least the number of Components
necessary to diligently perform BPS’ obligations under all then-current Plans [        *        ]. BPS 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 9 of 36	 	CONFIDENTIAL

 shall have no responsibility for delays in delivery of Drug Product resulting from delays in receipt of
Bulk Drug Substance or NUVELO-Supplied Components. In the event that BPS receives the Bulk Drug Substance for Production of Drug Product from NUVELO with less time than stated in the applicable Plan prior to the scheduled date of Production of such
Drug Product, as such scheduled date is set forth in the applicable Plan, but within sufficient time to Produce such Drug Product on such scheduled date, the sufficiency of the time required to Produce such Drug Product as reasonably determined by
BPS, BPS shall [        *        ] Produce such Drug Product as per the original schedule. In the event that BPS receives the Bulk Drug Substance for Production of Drug
Product from NUVELO with less time than stated in the applicable Plan prior to the scheduled date of Production of such Drug Product, as such scheduled date is set forth in the applicable Plan, and without sufficient time to Produce such Drug
Product on the scheduled date, the insufficiency of the time required to Produce such Drug Product as reasonably determined by BPS, BPS shall reschedule Production of such Drug Product and shall charge NUVELO the applicable Cancellation Fee.

  

	 	2.5	Importer of Record: In the event any material or equipment to be supplied by NUVELO, including without limitation NUVELO Supplied Components and Bulk Drug Substance, is
imported into the United States for delivery to BPS (the “Imported Goods”), such Imported Goods shall be imported DDP Bloomington, IN (Incoterms 2000). NUVELO shall be the “Importer of Record” of such Imported
Goods. As the Importer of Record, NUVELO shall be responsible for all aspects of the Imported Goods including, without limitation (a) customs and other regulatory clearance of Imported Goods, (b) payment of all tariffs, duties, customs,
fees, expenses and charges payable in connection with the importation and delivery of the Imported Goods, and (c) keeping all records, documents, correspondence and tracking information required by applicable laws, rules and regulations arising
out of or in connection with the importation or delivery of the Imported Goods. 

  

	 	2.6	Material Safety Data Sheet: NUVELO shall provide BPS a Material Safety Data Sheet for Bulk Drug Substance and for each Drug Product. Prior to Development or Production,
NUVELO shall notify BPS in writing of all usual or anticipated side effects resulting from exposure to the BDS or Drug Product that may occur as a result of all activities performed under this Agreement. BPS shall notify NUVELO in accordance with
Section 16.1, unless an individual is designated by NUVELO in writing to receive such notice in accordance with an applicable Plan, of any Exposure Event. BPS shall advise NUVELO immediately of any safety or toxicity problems of which it becomes
aware regarding the Drug Product. BPS shall perform its obligations under this Agreement in compliance with all Applicable Laws, specifically including any laws or regulations relating to personnel safety and environmental controls.

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 10 of 36	 	CONFIDENTIAL

	 	2.7	Vendor and Supplier Audit and Certification: NUVELO is responsible for assuring that vendors and suppliers of raw materials and Components used in the Production of Drug
Product have been certified and audited, as further set forth in the Quality Agreement. NUVELO shall provide BAXTER with a certification of audit for each manufacturer of BDS prior to Production from NUVELO’s quality assurance team.

  

	 	2.8	Storage: BPS shall store [        *        ] NUVELO EC Components
[        *        ] in a secure, environmentally-controlled and monitored location to prevent loss and damage thereto. NUVELO shall review BPS’ security during
its’ annual audits pursuant to Section 5.8. NUVELO Supplied Components (excluding the NUVELO EC Components) and Capital Equipment shall be stored by BPS in a secure location
[        *        ]. In no event shall BPS be required to store Drug Product for more than
[        *        ] days after Release of the Drug Product without BPS’ prior written consent and NUVELO’s agreement to reimburse BPS for all reasonable
costs incurred by BPS to continue with such storage after the initial [        *        ] day period. Acceptance and rejection of Drug Product are expressly addressed in
Article 6, and acceptance shall not be inferred from NUVELO’s taking delivery of Drug Product in accordance with this Section 2.8 or Section 2.9. 

  

	 	2.9	Delivery Terms: BPS shall deliver all Released Drug Product (or Drug Product being shipped under quarantine at the request of NUVELO and upon BPS consent, such consent not to
be unreasonably withheld or delayed) to a carrier designated by NUVELO FCA (Incoterms 2000) Bloomington, Indiana. Notwithstanding the preceding, BPS is responsible for the loading of the Drug Product onto or into the containers or trucks of the
carrier and shall bear all costs of such loading. NUVELO is responsible for the shipping costs, other than any costs associated with loading, and shall procure, at its cost, insurance covering damage or loss of the Drug Product during shipping or
while in the custody of the carrier. All shipping instructions of NUVELO shall be accompanied by the name and address of the recipient and the shipping date. 

  

	 	2.10	Subsequent Export: NUVELO represents that NUVELO is the owner of the goods that are consigned to BPS for contract manufacturing services. At no time does BPS assume ownership
or title to the goods. Where the goods are destined for subsequent export or re-export, NUVELO, as owner of the goods, warrants that NUVELO is responsible for any subsequent export or re-export and will comply with all applicable U.S. laws and
regulations relating to the export or re-export, including any applicable prohibition against unlawful transshipments. NUVELO and BPS each further agree that they shall not export or re-export any technical data received from the other Party or the
direct product of such technical data to any proscribed country listed in the U.S. Export Administration Regulations unless export or re-export of such data is properly authorized or otherwise is permitted by the U.S. Government.

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 11 of 36	 	CONFIDENTIAL

	 	2.11	Foreign Corrupt Practices Act: Each Party acknowledges that it is not the agent of the other Party and represents and warrants that it has not, and covenants that it will
not, pay anything of value to any government employee in connection with the resale of the Drug Product, obtaining Components or performing its obligations under this Agreement. 

  

	 	2.12	Returns: NUVELO shall be promptly notified in writing by BPS of any Drug Product returned to BPS by third parties. Drug Product returned by third parties is the
responsibility of NUVELO, subject to the other rights and remedies available to NUVELO under this Agreement, including, without limitation, replacement, refund, indemnity, and recall. 

 Article 3, Payment Terms. 
  

	 	3.1	Deposits and Payment for Drug Product and Development; Invoices: 

 3.1.1 If a Plan provides for a deposit to be made to BPS, NUVELO shall pay to BPS the deposit, if any, in accordance with the payment provisions for the deposit set forth in the applicable Plan. A deposit shall
not exceed [        *        ] of the costs of the services for which the deposit is being made, as such costs are set forth in the applicable Plan. In the event of
termination by NUVELO as a result of a material breach by BPS pursuant to Section 4.2.1, by NUVELO pursuant to Section 4.2.2.2 or as a result of a force majeure termination pursuant to Section 8.1, BPS shall reimburse to NUVELO the
amount of any and all deposits under any then-current Plans, to the extent that there is any remainder after NUVELO has paid the fees due to BPS upon such termination as set forth in Section 4.4. 
 3.1.2 NUVELO shall pay to BPS the fees, costs and expenses set forth in each applicable Plan in accordance with the terms and conditions set forth
in this Agreement and the applicable Plan for such payment. BPS shall invoice NUVELO for the fees, costs and expenses established in each applicable Plan, after the applicable fees, costs and expenses become due and payable in accordance with this
Agreement and the applicable Plan. 
 3.1.3 Upon completion of filling of a Batch of Drug Product as set forth in the applicable
Project Plan, BPS shall invoice NUVELO for the remainder of the Batch Purchase Price for such Batch in accordance with the terms set forth in Section 3.1.4. NUVELO shall pay, in full, the invoice for the remainder of the Batch Purchase Price in
accordance with the terms set forth in Section 3.1.4, so long as: (i) [        *        ]; and (ii) NUVELO has not notified BPS, before the expiration of the
Document Review Period, that the Batch is Non-Conforming. If NUVELO receives the Release Documentation later than [        *        ] then
[        *        ] the Document Review Period, so 
 [ * ] Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 12 of 36	 	CONFIDENTIAL

 long as NUVELO has not notified BPS that the Batch is Non-Conforming before the expiration of the
Document Review Period. If NUVELO notifies BPS, before the expiration of Document Review Period, that the Batch is Non-Conforming, then: (a) [        *        ] the
Document Review Period; and (b) [        *        ] set forth in the invoice will become due and payable, if: (1) the Parties, or an independent expert or
independent laboratory in accordance with Section 6.1.3, determines that the Non-Conformity is not due to a BPS failure in accordance with Article 6, or (2) BPS has produced a conforming, replacement Batch, with payment due upon
re-invoicing [        *        ] in accordance with Section 3.1.4. 
 3.1.4 Except as otherwise expressly provided in Section 3.1.3, NUVELO shall pay invoices for fees, costs and expenses due and payable in accordance with the applicable Plan and this Agreement before the
expiration of [        *        ] days after the date of the invoice for those due and payable fees, costs and expenses, so long as BPS has sent
[        *        ] the applicable invoice to NUVELO’s accounts payable department no later than
[        *        ]. If an invoice is not received by NUVELO, [        *        ], to its
accounts payable department, before the expiration of [        *        ] days after the invoice date, the invoice becomes due and payable
[        *        ] the applicable invoice, except as otherwise expressly provided in Section 3.1.3. Any payment due under this Agreement in accordance with the
terms and conditions of this Agreement that is not received in accordance with this Section 3.1.4 shall bear interest at the lesser of (a) the maximum rate permitted by law, or
(b) [        *        ] per month on the outstanding balance. BPS shall provide NUVELO with a written response or resolution to any disputed invoices within
[        *        ] days from notice from NUVELO of the dispute. Payments hereunder may be made by check or wire transfer. 
 3.2 Capital Equipment: Any and all costs associated with the purchase, delivery, handling, installation and maintenance of any capital equipment
purchased in accordance with a Plan (“Capital Equipment”) shall be expressly set forth in the applicable Plan executed by both of the Parties, and the title to Capital Equipment belongs to NUVELO. BPS shall use commercially
reasonable efforts to maintain all Capital Equipment in good working order, as further set forth in detail in the Quality Agreement. 
 3.3
Default in Payment Obligations: In addition to the remedies available to BPS in the event of a material breach of the Agreement by NUVELO, if NUVELO fails to make payments for undisputed invoices as set forth in Section 3.1.3 and 3.1.4 or
undisputed cancellation fees, during the period in which NUVELO remains in default on the applicable payment, BPS may: [        *        ]; or
[        *        ]. 
 [ * ] Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 13 of 36	 	CONFIDENTIAL

 If NUVELO defaults on undisputed payment obligations under this Agreement
[        *        ], then, until NUVELO has been without a default on an undisputed payment obligation for
[        *        ] BPS may require [        *        ]. Once NUVELO has been without a
default in its undisputed payment obligations for a period of [        *        ] unless NUVELO has a subsequent default on an undisputed payment obligation. Upon
[        *        ] BPS may again require [        *        ] until NUVELO has been
without a default in its undisputed payment obligations for a continuous period of [        *        ]. 
  

	 	3.4	Cancellation Fees: In the event of cancellation by NUVELO of the Production of any Batch set forth in a Project Plan or in the event of termination of this Agreement, except
in the event of termination by NUVELO of a Plan or the Agreement for material breach by BPS pursuant to Section 4.2.1, termination of the Agreement pursuant to Section 4.2.2.2 or in the event of a force majeure termination pursuant to
Section 8.1, NUVELO shall pay the Cancellation Fees as hereinafter set forth: (i) NUVELO is subject to a charge of [        *        ] of the Batch Purchase
Price if the Batch is canceled less than [        *        ] weeks from the scheduled fill date set forth in the applicable Plan, (ii) a charge of
[        *        ] of the Batch Purchase Price if the Batch is canceled less than
[        *        ] from the scheduled fill date set forth in the applicable Plan, and (iii) a charge of
[        *        ] of the Batch Purchase Price if the Batch is canceled less than
[        *        ] from the scheduled fill date set forth in the applicable Plan. For purposes of the foregoing, one (1) week is equivalent to seven
(7) calendar days. 

  

	 	3.5	Earned Value Analysis Report: Within five (5) business days after the end of each month, BPS will provide a financial earned value analysis report for that month to
NUVELO. This report will summarize the approximate value of services provided to NUVELO for each stage of the Plans that BPS actively performed under during that month. NUVELO will use this information for monthly accrual purposes only.

 Article 4, TERM, TERMINATION AND BANKRUPTCY. 
  

	 	4.1	Term: This Agreement commences on the Effective Date and continues until the Development and Production, as described in each Development Plan and Project Plan, have all been
completed, unless sooner terminated pursuant to Section 4.2 (the “Term”). 

  

	 	4.2	Termination: This Agreement may be terminated as follows: 

  

	 	4.2.1	Termination for Breach. Either Party may terminate this Agreement upon the material breach of any provision of this Agreement by the other 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 14 of 36	 	CONFIDENTIAL

 Party if such material breach is not cured by the breaching Party within
[        *        ] days after receipt by the breaching Party of written notice of material breach for monetary defaults, and
[        *        ] days after receipt by the breaching Party of written notice of material breach for non-monetary defaults (or such additional time as is reasonably
necessary to cure such non-monetary default if and only if the breaching Party has commenced a cure within the [        *        ] day period and is diligently pursuing
completion of such cure). At the option of the non-breaching Party, such termination may be with respect to the entire Agreement, or only with respect to the Plan that is subject to the material breach. ‘ 
  

	 	4.2.2	Termination Without Cause and for BPS SOP Change. 

  

	 	4.2.2.1	NUVELO may terminate any Plan or this Agreement for any reason by providing
[        *        ] days prior written notice to BPS subject to the provisions of Sections 3.4 and 4.4. 

  

	 	4.2.2.2	NUVELO may terminate any Plan or this Agreement in accordance with the terms of Section 6.1.2, subject to the provisions of Section 4.4 and expressly not subject to the
provisions of Section 3.4. 

  

	 	4.2.3	Termination for Force Majeure. Either Party may terminate this Agreement in accordance with the terms set forth in Section 8.1 subject to the provisions of
Section 4.4. 

  

	 	4.3	Bankruptcy: The license granted under Section 11.5.1 of this Agreement, including amendments hereto, by BPS to NUVELO is, for purposes of Section 365(n) of Title 11 of
the U.S. Code (“Title 11”), a license of rights to “intellectual property” as defined in Title 11. 

  

	 	4.4	Payment on Termination: In the event of the termination of this Agreement, NUVELO shall pay to BPS the actual cost to BPS of: (a) any BPS Supplied Components or Capital
Equipment not already paid for by NUVELO, ordered by BPS in accordance with an applicable Plan prior to BPS’ date of receipt of the notice of termination and not cancelable at no cost to BPS, so long as such BPS Supplied Components or Capital
Equipment are made reasonably available for delivery to NUVELO pursuant to Section 2.9 for [        *        ] days after BPS’ date of receipt of such notice,
whether or not NUVELO decides to take delivery of the BPS Supplied Components; (b) all work-in-process commenced by BPS prior to the date of receipt by BPS of notice of termination, but only work conducted in accordance with the terms and
conditions of this Agreement and the applicable Plan, if this Agreement is being terminated for material breach by BPS or terminated in accordance with Section 4.2.2.2; and (c) all Released Drug Product delivered to NUVELO pursuant to
Section 2.9, unless NUVELO is entitled to a refund of the Batch Purchase Price in accordance with the terms and conditions of Article 6. 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as
amended. 
  

					
	NUVELO	 	Page 15 of 36	 	CONFIDENTIAL

	 	4.5	Return of Materials: Following any expiration or termination of this Agreement, BPS shall promptly ship all Deliverables, Capital Equipment and Master Batch Records to NUVELO
at NUVELO’s cost and per NUVELO’s instructions. NUVELO shall make payment for costs and expenses due and payable to BPS in accordance with Sections 3.4 and 4.4, if applicable, in accordance with Sections 3.1.3 and 3.1.4.

  

	 	4.6	Survival: Termination or expiration of this Agreement through any means or for any reason, shall be without prejudice to obligations previously accruing or the rights and
remedies of either Party with respect to any antecedent breach of any of the provisions of this Agreement. The provisions of Articles 4, 7, 10 and 13 through 16, and Sections 3.1, 3.4, 3.5, 5.2, 5.3, 5.6, 5.8, 6.1 through 6.3, 11.1 through 11.4,
11.5.1, 11.6 through 11.9, 12.3, and 12.5 hereof survive expiration or termination of this Agreement for the period specified in the applicable section or article, or if no period is specified, the maximum amount of time permitted by applicable law.

 Article 5, QCMD AND MANUFACTURING COMPLIANCE. 
  

	 	5.1	QCMD and Release Testing: At NUVELO’s cost and expense, BPS shall test, or cause to be tested by third parties in accordance with Section 5.2 and in accordance with
the Specifications, each Batch of Drug Product Produced pursuant to this Agreement for Release before Final Release and delivery to NUVELO pursuant to Section 2.9. The QCMD shall contain the Certificate of Analysis for each Batch to be
delivered, the items tested, the Specifications, and the test results. Any material change to an approved QCMD will be reviewed and approved by BPS and by NUVELO prior to the change being implemented. The Parties acknowledge that the following are
examples of material changes to the QCMD: any change that is determined to be a material change to the QCMD in accordance with the Quality Agreement; and any change to a QCMD that is, involves or results in a change to any Specification. BPS shall
confirm on the final page of the Released Executed Batch Record for each Batch that all Batch Production and control records have been reviewed and approved by the appropriate quality unit in accordance with the Quality Agreement. BPS shall send, or
cause to be sent, the Release Documentation to NUVELO to enable NUVELO to determine whether the applicable Batch can be Finally Released and thereafter delivered to NUVELO’s carrier pursuant to Section 2.9 (unless Drug Product is shipped
under quarantine at the written request of NUVELO pursuant to Section 2.9). As required by the FDA, NUVELO assumes full responsibility for Final Release of each Batch of Drug Product. 

  

	 	5.2	Use of Third Party Subcontractors: Except as expressly permitted in an applicable Plan, or proper amendment thereof, BPS shall not subcontract or otherwise assign any of its
primary responsibilities regarding the formulation and fill of NUVELO’s Drug Product, except as permitted pursuant to Section 16.4. Should BPS be directed by NUVELO to subcontract, or should BPS otherwise 

  

					
	NUVELO	 	Page 16 of 36	 	CONFIDENTIAL

 intend to subcontract to any third party its obligations regarding testing of NUVELO’s Drug Product
done during Production, NUVELO and BPS will agree, in the applicable Plan, upon the laboratory or laboratories, or contractor or contractors, that shall perform such testing. If NUVELO requests testing to be done by any laboratory that is not a
BPS-audited laboratory in good standing with BPS, then NUVELO shall contract with such laboratory, and any testing results of such laboratory will not be included by BPS on the Certificate of Analysis section of BPS’ QCMD, and such testing
shall be removed from the scope of the applicable Plan and this Agreement. For the avoidance of doubt, the foregoing restrictions on subcontracting shall not be deemed to apply to individuals that work as individual contributors at BPS’
Bloomington, Indiana facility, and that are bound by contractual obligations to BPS to comply with all of the terms and conditions of this Agreement (“Leased Employees”). BPS is expressly liable for any breach of the terms of this
Agreement by any of its Leased Employees, [        *        ]. BPS shall not engage or use any subcontractors or individuals or entities to perform under this Agreement
that are not: BPS employees; Leased Employees; BPS-approved laboratories performing work under contract with BPS; subcontractors performing work for or at BPS’ facility in Bloomington, Indiana; or any other subcontractors authorized pursuant to
this Section 5.2. 
  

	 	5.3	Manufacturing Compliance: BPS shall advise NUVELO immediately if an authorized agent of any regulatory body visits BPS’ manufacturing facility and makes an inquiry
regarding BPS’ Production of Drug Product for NUVELO. NUVELO shall advise BPS immediately if an authorized agent of any regulatory body plans to visit, or accompany NUVELO on a visit to, BPS’ manufacturing facility. Manufacturing
exceptions which occur during Production of Drug Product that do not cause the Production to be non-compliant with cGMP and do not prevent the Drug Product from being Finally Released shall not be deemed to cause such Drug Product to be
Non-conforming. 

  

	 	5.4	Reserve Samples: NUVELO shall be responsible for obtaining and maintaining sufficient quantities of Bulk Drag Substance reserve samples and Drug Product reserve samples
pursuant to cGMP. 

  

	 	5.5	Annual Quality Review: As part of NUVELO’s annual quality assurance audit, in accordance with Section 5.8, NUVELO shall evaluate, at least annually, the quality
standards of Drug Product to determine the need for any changes in Specifications, manufacturing processes, and/or controlled documents. NUVELO shall supply BPS a copy of the final audit report, including any evaluation and recommendations
incorporated in the report. 

  

	 	5.6	Distribution Records: BPS shall maintain distribution records that contain all of the appropriate information as specified in, and as necessary to comply with, cGMP.

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities NUVELO and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 17 of 36	 	CONFIDENTIAL

	 	5.7	Customer Complaints and Adverse Events: NUVELO, as required by cGMP, shall maintain all customer complaint and adverse event files. Any such complaints received by BPS shall
be forwarded to NUVELO. NUVELO shall be responsible for the review of the complaint or adverse event to determine the need for an investigation or the need to report to the FDA as required by cGMP. NUVELO shall send to BPS all Drug Product
performance or manufacturing-related complaints that relate to BPS’ Production which require investigation and shall provide to BPS reasonable samples of all Drug Product which is the subject of such complaints. BPS shall conduct an
investigation for each Drug Product performance or manufacturing-related complaint for which BPS receives a sample and shall report findings and follow-up of each investigation to NUVELO. NUVELO shall make these complaint files available to BPS if
and to the extent that they are required during an FDA inspection. 

  

	 	5.8	Audits and QP Access: NUVELO, upon prior written notice and during normal business hours, shall have the right to inspect and audit, once annually, BPS Batch records, the
Master Batch Records, and the portions of BPS’ facility used for Production of Drug Product, as further specified in the Quality Agreement; provided, however that NUVELO shall have the right to perform an additional audit or audits or
inspections of such Batch records and facility if such additional audit is for cause including without limitation the need to resolve issues raised in the immediately preceding annual audit. For the avoidance of doubt, the providing of certain
financial information to NUVELO is addressed in Section 3.5. If NUVELO chooses to audit BPS more than once in a calendar year other than for cause, NUVELO will reimburse BPS for BPS’ reasonable expenses incurred in hosting the audit,
[        *        ], the audit is conducted [        *        ]. All audited data will be
treated as Confidential Information of BPS, and NUVELO shall not be permitted to remove or copy data without BPS’ prior written consent. NUVELO will be responsible for providing a Qualified Person (“QP”) for European Union
regulatory compliance. Any individual or entity that is operating as NUVELO’s QP for the purposes of European Union regulations for the manufacture and sale of medicinal products will have reasonable access to BPS’ facilities and
documentation related to the Production of Drug Product as necessary to conduct the individual or entity’s work as the QP. BPS will work with NUVELO’s QP as reasonably necessary to enable NUVELO’s QP to accomplish its duties as QP.
This Section 5.8 survives any expiration or termination of this Agreement until [        *        ]. 

  

	 	5.9	Regulatory Compliance: BPS is responsible for compliance with, and shall comply with, all Applicable Laws. NUVELO shall be responsible for compliance with all Applicable Laws
as they apply to NUVELO’s manufacture, use, and sale of Drug Product, which responsibility shall include, without limitation, all contact with the FDA regarding the foregoing, except to the extent expressly provided otherwise in the Quality
Agreement. 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 18 of 36	 	CONFIDENTIAL

 Article 6, ACCEPTANCE/RELEASE OF DRUG PRODUCT. 
  

	 	6.1	Non-Conforming Drug Product/Final Release: Within [        *        ] days after the date of
Production of any Batch pursuant to the Project Plan, BPS shall, if requested by NUVELO, promptly forward to NUVELO, or NUVELO’s designee, samples of such Batch. Within
[        *        ] days after receipt by NUVELO of the samples, if requested, or
[        *        ] days after receipt by NUVELO of the Release Documentation (this
[        *        ] day period referred to as the “Document Review Period”), whichever is later, NUVELO shall determine, based upon its review and
evaluation of the Release Documentation, whether the Drug Product conforms to [        *        ] (collectively, the “Product Requirements”). NUVELO is
entitled to, but has no obligation to BPS to, perform any post-Release testing on Drug Product. 

  

	 	6.1.1	Determination of Final Release: A Batch of Released Drug Product shall be deemed to have been accepted by NUVELO and NUVELO shall have waived its right to revoke acceptance
if: (a) in accordance with Section 6.1.3, the independent expert or laboratory determines that Drug Product conforms to the Product Requirements; or (b) NUVELO fails to notify BPS within the time period set forth in Section 6.1
above that the Batch of Drug Product does not conform to the Product Requirements. 

  

	 	6.1.2	Non-Conformities. If NUVELO believes a Batch of Drug Product does not conform to the Product Requirements, or if NUVELO believes that
[        *        ] that occurs after the relevant Project Plan was executed by the Parties (except
[        *        ] pursuant to this Section 6.1.2), caused the Drug Product to not meet
[        *        ] that were [        *        ] (any such failure(s) or change(s)
referred to individually as a “Non-conformity,” a Batch Produced with a Non-Conformity referred to as “Non-conforming”), NUVELO shall notify BPS in a writing setting forth a detailed description of why the
Batch of Drug Product is Non-conforming and provide such written documentation to BPS via overnight courier delivery. Upon receipt of such notice, BPS will investigate such alleged Non-conformity, and: (i) if BPS agrees such Drug Product is
Non-conforming, deliver to NUVELO a detailed corrective action plan with an estimated timeline for such corrections within [        *        ] days after receipt of
NUVELO’s written notice of Non-conformity, or such additional time as is reasonably required if such investigation or plan requires data from sources other than NUVELO or BPS, but in no case longer than the time established in Section 6.2
or (ii) if BPS disagrees with NUVELO’s determination that the Batch of Drug Product is Non-conforming, BPS shall so notify NUVELO of the dispute in writing 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and
Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 19 of 36	 	CONFIDENTIAL

 within
[        *        ] days after receipt of NUVELO’s notice of Non-conformity (any such dispute, and any dispute regarding the cause, or causes, of a Non-Conformity,
referred to as a “Batch Dispute”). Notwithstanding any other language in this Article, NUVELO is [        *        ] and approved
[        *        ]; and BPS is not responsible for [        *        ], so long as:
(a) [        *        ]; (b) [        *        ] and
(c) [        *        ], NUVELO has [        *        ]. If BPS
[        *        ] NUVELO [        *        ], BPS shall have
[        *        ] days from receipt thereof to notify NUVELO in writing or Electronically that BPS
[        *        ] or will [        *        ]. If NUVELO does not receive
[        *        ] from BPS before the expiration of [        *        ] days after
[        *        ], NUVELO may, in its discretion, no later than [        *        ]
days after [        *        ], send BPS a notice of termination of the Agreement in accordance with Section 4.2.2.2, which termination shall become effective
[        *        ] days after receipt of the notice of termination by BPS. Once BPS receives
[        *        ], BPS shall not [        *        ] until the earlier of
[        *        ] NUVELO to [        *        ] of the
[        *        ] the expiration of [        *        ] days after BPS’ receipt of
[        *        ]. 
  

	 	6.1.3	Batch Disputes. If NUVELO and BPS cannot resolve a Batch Dispute or agree upon an independent expert or laboratory to resolve a Batch Dispute before the expiration of
[        *        ] days after NUVELO receives BPS’ notice of a Batch Dispute, then each Party shall nominate an independent expert who shall not: be a current or
former employee, consultant or agent of a Party; have an immediate family member who is an employee, consultant or agent of a Party; or have any financial interest in a Party. Promptly thereafter, those two (2) independent experts shall agree
on a third independent expert who shall, or who shall select an independent third party laboratory to, conduct the work necessary to promptly resolve the Batch Dispute. Such referral shall be solely for the purpose of establishing whether or not the
applicable Batch is Non-conforming, and the cause, or causes, of the Non-conformity. Each Party shall provide the independent expert or independent laboratory with all Information reasonably related to the Batch Dispute that is requested by the
independent expert or independent laboratory for the resolution of the Batch Dispute, but excluding any confidential Information belonging to 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as
amended. 
  

					
	NUVELO	 	Page 20 of 36	 	CONFIDENTIAL

 any other customer of BPS or any collaborator of NUVELO. The decision of the independent expert or
laboratory, as set forth above, shall be made in writing and shall be binding upon the Parties. Whichever Party failed to accurately determine whether a Non-conformity existed, or if a Non-Conformity is confirmed to exist, whichever Party fails to
accurately determine whether a BPS failure resulted in the Non-conformity, shall bear the full cost and expense associated with the hiring and performance of the independent experts and/or laboratory. 
  

	 	6.2	Remedies for Non-conforming Drug Product: In the event BPS agrees that the Batch of Drug Product is Non-conforming or the independent expert or independent laboratory
determines that the Batch of Drug Product is Non-conforming, to the extent that the Batch is Non-conforming as a result of a failure by BPS to conform to the Product Requirements, or to the extent
[        *        ] caused the Drug Product not to conform to [        *        ] (as set
forth and limited by Section 6.1.2), as determined by the Parties or the independent expert or independent laboratory, at NUVELO’s option and discretion, BPS shall either: (i) refund the Batch Purchase Price of the Non-conforming
Batch of Drug Product [        *        ]; or (ii) at BPS’ cost and expense, (subject to NUVELO at its expense supplying the replacement Bulk Drug Substance),
replace such Non-conforming Batch of Drug Product with a replacement Batch of Drug Product within sixty (60) calendar days from receipt of replacement Bulk Drug Substance from NUVELO, except that if the Non-conforming Batch, or any
Non-conforming replacement Batch, did not result solely from a failure by BPS to conform to the Product Requirements, BPS’ consent to the Production of the replacement Batch, such consent not be unreasonably withheld, will need to be obtained
before any replacement Batch of Drug Product is Produced. 

  

	 	6.3	Non-conforming Bulk Drug Substance: If a Batch of Drug Product is rejected by NUVELO, and such Batch of Drug Product’s failure to conform to the Product Requirements is
the result of non-conforming Bulk Drug Substance, then the rejected Batch of Drug Product shall not be deemed to be Non- conforming as a result of a failure of BPS to conform to the Product Requirements. 

  

	 	6.4	Reproduction, Rework or Reprocessing: If during the Production of any Batch of Drug Product, any reproduction or reprocessing is required in order for the Batch to meet the
Specifications for Drug Product, BPS shall conduct, at its sole cost and expense and subject to Section 6.2, such reproduction or reprocessing in compliance with Applicable Laws, cGMPs and the BLA. Any reproduction or reprocessing which is not
covered by Applicable Laws, cGMPs or the BLA must be approved in writing by NUVELO prior to implementation. BPS shall not perform any rework of any kind whatsoever on any Batch without the prior written or prior Electronically-documented consent of
an authorized representative of NUVELO. Unless reproduction, NUVELO-approved rework, or reprocessing, is required as a result of a Non-conformity, such reproduction, 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and
Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 21 of 36	 	CONFIDENTIAL

 rework or reprocessing shall be set forth in an amendment to the applicable Plan and NUVELO shall be
responsible for, and promptly reimburse BPS for the costs and expenses incurred for performance of such reproduction, NUVELO-approved rework, or reprocessing as such costs and expenses are set forth in the amendment to the applicable Plan.
Reinspection, relabeling, or repackaging shall not be considered reproduction, rework, or reprocessing. 
 Article 7, DRUG PRODUCT RECALLS.

  

	 	7.1	Drug Product Recalls: In the event NUVELO shall be required to recall any Drug Product because such Drug Product may violate local, state or federal laws or regulations, the
laws or regulations of any applicable foreign government or agency or the Specifications for Drug Product, or in the event that NUVELO elects to institute a voluntary recall, NUVELO shall be responsible for coordinating such recall. NUVELO promptly
shall notify BPS if any Drug Product is the subject of a recall as a result of any of the services performed in accordance with this Agreement and provide BPS with a copy of all documents relating to such recall. BPS shall cooperate with NUVELO in
connection with any recall. To the extent a recall is caused by [        *        ], or
[        *        ] and such recall occurs within [        *        ] of the date of
manufacture, BPS shall bear all reasonable costs and expenses associated with the recall [        *        ]. Notwithstanding the foregoing,
[        *        ] 

  

							
		
	 *
	  	    *

	  	 *
	  	 *
	  	 *

				
	 *
	  	 *
	  	 *
	  	 *

				
	 *
	  	 *
	  	 *
	  	 *

				
	 *
	  	 *
	  	 *
	  	 *

				
	 *
	  	 *
	  	 *
	  	 *

				
	 *
	  	 *
	  	 *
	  	 *

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 22 of 36	 	CONFIDENTIAL

 Article 8, FORCE MAJEURE. 
  

	 	8.1	Force Majeure Events: Failure of either Party to perform under this Agreement (except the obligation to make payments) shall not subject such Party to any liability to the
other Party for delays in performance if such failure results from any cause outside the reasonable control of the affected Party, including acts of God, acts of terrorism, fire, explosion, flood, war, riot, sabotage, embargo, strikes or other labor
trouble, compliance with any unanticipated order or regulation of any government entity, so long as written notice of such event is promptly given to the other Party and the affected Party uses commercially reasonable efforts to resume performance
as soon as possible once the force majeure has resolved. The unaffected Party shall have no obligation to make any payments to the affected Party for the performance of work that has not been conducted, or has been delayed, due to the force majeure
event until the performance of such work has been resumed by the affected Party. If the affected Party does not resume performance within [        *        ] days after
the force majeure event has resolved, the other Party may terminate this Agreement upon [        *        ] days notice to the affected Party. 

Article 9, CHANGES IN PRODUCTION. 
  

	 	9.1	Changes to DPS SOPs and Specifications for Drug Product: BPS shall provide NUVELO with
[        *        ] any proposed change to Specifications for Drug Product or the DPS SOPs. No changes to DPS SOPs or Specifications for Drug Product will be made
without NUVELO’s prior written, or prior Electronically-documented, approval. 

  

	 	9.2	Drug Product-Specific Changes: If unanticipated facility, equipment, process or system changes are required of BPS as a result of requirements set forth by the FDA or any
other Regulatory Authority, and such regulatory changes apply specifically and solely to the Production and supply of one (1) or more Drug Products, then NUVELO and BPS will review such requirements and agree in writing to such regulatory
changes, and [        *        ] the reasonable, actual costs thereof. 

  

	 	9.3	General Changes: If regulatory changes are required as a result of requirements set forth by the FDA or another Regulatory Authority, and such regulatory changes apply
generally to one (1) or more Drug Products as well as to other products produced by BPS for itself or for third parties, then [        *        ] of the reasonable
cost of such regulatory changes [        *        ] facility is dedicated to the Production of Drug Products during a calendar year period
[        *        ] other products, as shown by BPS written records. 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as
amended. 
  

					
	NUVELO	 	Page 23 of 36	 	CONFIDENTIAL

 Article 10, CONFIDENTIALITY. 
  

	 	10.1	Prior Confidentiality Agreement. This Agreement, by reference, supersedes the Confidentiality Agreement signed by NUVELO and BPS on May 27, 2005, solely with respect to
the subject matter of this Agreement. 

  

	 	10.2	Confidentiality. Except as otherwise expressly stated in this Article 10, Receiving Party will keep Confidential Information confidential and shall not disclose Confidential
Information to third parties or publicly without Disclosing Party’s prior written consent. Except as otherwise expressly stated in this Article 10, Receiving Party shall not use, copy or distribute Confidential Information in any manner
whatsoever, in whole or in part, except for the purposes of fulfilling its obligations under this Agreement. Without the prior written consent of the Disclosing Party, Receiving Party may disclose Confidential Information to its, and its
Affiliates’, employees, Leased Employees and contractors authorized by Section 5.2, attorneys, accountants and agents (“Permitted Recipients”) who need to know Confidential Information for the purposes set forth in
the Agreement and who are bound by obligations of confidentiality and non-use with respect to Confidential Information that are no less stringent than the terms and conditions set forth in this Agreement. Receiving Party will use at least the same
level of care to protect Confidential Information as it uses to protect is own information of similar nature, but not less than a reasonable level of care. Receiving Party is liable for any breach of this Agreement by its Permitted Recipients.
NUVELO may disclose Confidential Information to its collaboration partners upon BPS’ prior written consent, such consent not to be unreasonably withheld. BPS expressly consents to the disclosure of Confidential Information to NUVELO’s
collaboration partner, Bayer Healthcare AG, and Bayer Healthcare AG is a Permitted Recipient of NUVELO. Unless otherwise expressly provided in this Agreement, Confidential Information is and remains the sole and exclusive property of the Disclosing
Party. No provision of this Agreement shall be construed so as to preclude NUVELO from disclosing the Confidential Information of BPS as may be reasonably necessary to secure from any Regulatory Authority necessary approvals or licenses with respect
to the Drug Product. 

  

	 	10.3	Permitted Disclosure: Each Party may disclose Confidential Information hereunder to the extent such disclosure is required to comply with applicable law, governmental
regulations, court orders or, solely with respect to NUVELO, for the purpose of conducting pre-clinical or clinical trials, if and only if the Party required to make the disclosure of the other Party’s Confidential Information, except where
impractical for necessary disclosures, for example in the event of a medical emergency, gives the Disclosing Party reasonable advance notice of the disclosure requirement and uses good faith efforts to assist the Disclosing Party to secure a
protective order or confidential treatment of such Confidential Information required to be disclosed. 

  

					
	NUVELO	 	Page 24 of 36	 	CONFIDENTIAL

	 	10.4	Limitation of Disclosure of Agreement: Except as otherwise may be authorized by Section 10.3 or required by, or necessary to comply with applicable laws, regulations,
rules or orders, including without limitation the rules and regulations promulgated by the United States Securities and Exchange Commission (the “SEC”) as set forth in Section 10.5 below, no information concerning this
Agreement, the terms herein, or the transactions contemplated herein shall be made public by either Party without the prior written consent of the other. 

  

	 	10.5	Publicity and SEC Filings: Except as otherwise provided in Section 10.4 or this Section 10.5, any public announcement of the execution of this Agreement may only be
by one or more press releases mutually agreed to by the Parties. Unless the prior written consent of the other Party is obtained, no Party shall, except as may be otherwise allowed under Section 10.3 or required by, or necessary to comply with
any SEC filing requirements, in any manner disclose or advertise or publish or release for publication any statement mentioning the other Party or information contained in this Agreement, or the existence of this Agreement, or the fact that any
Party has furnished or contracted to furnish the other Party the items required by this Agreement, or quote the opinion of any employee of the other Party. In the event a Party is required by any SEC filing requirements to disclose such information
(the “Discloser”), or it is necessary to disclose such information to comply with any SEC filing requirements, the other Party (“Non-Discloser”) shall cooperate fully and in a timely manner with the Discloser with
respect to all disclosures to the SEC; the Discloser will give the Non-Discloser a reasonable opportunity to review the information to be disclosed and provide the Discloser with proposals regarding requests for confidential treatment for such
information. Notwithstanding anything else in this Agreement, NUVELO may disclose this Agreement, its terms, conditions and exhibits in filings with the SEC as necessary to comply with the rules and regulations promulgated by the SEC in all
instances, without any limitation upon such disclosure. Notwithstanding anything else in this Article 10, either Party may communicate to its investors, third parties and the public any information disclosed publicly or made publicly available in
accordance with this Article 10. 

  

	 	10.6	Duration of Confidentiality: All obligations of confidentiality and non-use imposed upon the Parties under this Agreement shall expire
[        *        ] years after the expiration or earlier termination of this Agreement. 

  

	 	10.7	Other Initiatives: Each Party understands that the other Party may have present or future initiatives, including initiatives with third parties, involving similar products,
technologies or processes that compete with a product, technology or process contemplated or offered by the other Party. Accordingly, each Party acknowledges that, so long as the terms and conditions of this Agreement are not breached, nothing in
this Agreement shall be construed as a representation or inference that the other Party will not develop for itself or enter into business relationships with other third parties, that involve products, technologies or processes that are similar or
compete with any product, technology or process contemplated or offered by the other Party. 

 [ * ] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 25 of 36	 	CONFIDENTIAL

 Article 11, DELIVERABLES; INVENTIONS. 
  

	 	11.1	Existing Intellectual Property: Except as otherwise expressly set forth in this Agreement, each Party shall continue to own the patents, trademarks, copyrights, trade secrets
and other intellectual property it owned on or before the Effective Date of this Agreement, without conferring any interests therein on the other Party. Without limiting the generality of the preceding sentence, NUVELO owns and shall retain all
right, title and interest in and to its existing interests in any and all Drug Product, Bulk Drug Substance, Labeling and trademarks associated therewith, and any intellectual property rights of any kind, located anywhere in the world that claim or
otherwise cover Drug Product, Bulk Drug Substance and Labeling, including without limitation any claim to a method of use of any of the preceding, or any formulation, dosage, administration or method of manufacture of the preceding (collectively,
“NUVELO’s Intellectual Property”). Neither BPS nor any third party shall acquire any right, title or interest in NUVELO’s Intellectual Property by virtue of this Agreement or otherwise. 

  

	 	11.2	Inventions: “Invention” shall mean any innovation, invention, improvement, development, discovery, computer program, device, trade secret, method,
know- how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable. 

  

	 	11.3	NUVELO Inventions: “NUVELO Inventions” shall mean all Inventions which are conceived, reduced to practice, or created: (a) solely by NUVELO or its
Permitted Recipients during the term of this Agreement; or (b) by BPS or its Permitted Recipients in the course of performing BPS’ obligations under this Agreement either solely or jointly with NUVELO: (i) which embody modifications
or improvements to the Drug Product or Bulk Drug Substance; or (ii) are methods of manufacture [        *        ] manufacture of the Drug Product or Bulk Drug
Substance. NUVELO Inventions are solely owned by NUVELO, and BPS assigns all right, title and interest it may have in and to NUVELO Inventions to NUVELO. NUVELO has the right, but not the obligation, to seek patent and any other form of applicable
intellectual property protection, at its sole expense, for any NUVELO Inventions. BPS will take all actions reasonably necessary to vest in NUVELO all right, title and interest in and to the NUVELO Inventions. All Material Deliverables are owned by
NUVELO and Information Deliverables which are [        *        ] are deemed to be NUVELO Confidential Information. 

  

	 	11.4	BPS Inventions: “BPS Inventions” shall mean all Inventions, other than NUVELO Inventions, which are conceived, reduced to practice, or created solely by BPS and its
Permitted Recipients in the course of performing their obligations under this Agreement. BPS Inventions shall be solely owned by BPS. 

 [ * ]
Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.

  

					
	NUVELO	 	Page 26 of 36	 	CONFIDENTIAL

	 	11.5	License Grants: 

  

	 	11.5.1	BPS hereby grants to NUVELO a non-exclusive [        *        ] worldwide,
[        *         ] license, with the right to sublicense through multiple levels of sublicensees, under and to all BPS Inventions, to research, develop, conduct
clinical trials for, formulate, manufacture, test, seek regulatory approval for, market, commercialize, make, have made, use, sell, offer for sale, import, distribute and otherwise exploit the Bulk Drug Substance and any final dosage, capped,
packaged or labeled form of the BDS. 

  

	 	11.5.2	NUVELO hereby grants to BPS a non-exclusive license, without the right to sublicense except to sublicensees pre-approved in writing by NUVELO in accordance with
Section 5.2, to use NUVELO’s Intellectual Property and NUVELO Inventions during the Term of this Agreement solely as necessary to perform Production and Development for NUVELO in accordance with the terms and conditions of this Agreement
and any applicable Plans, and for no other use or purpose. 

  

	 	11.6	Jointly Owned Inventions: All Inventions, other than NUVELO Inventions, which are conceived, reduced to practice, or created in the course of the performance of the Agreement
jointly by the Parties or jointly by a least one (1) Permitted Recipient of each of the Parties, who would be or are properly named as co-inventors under the laws of the United States on any patent application claiming such Inventions, shall be
owned jointly by the Parties. Each Party shall have full rights to exploit such Inventions for its own commercial purposes without any obligation or accounting to the other. The Parties shall share equally (50:50) in the cost of mutually agreed
patent filings with respect to all such jointly owned Inventions. The decision to file for patent coverage on jointly owned Inventions shall be mutually agreed upon, and the parties shall select a mutually acceptable patent counsel to file and
prosecute patent applications based on such jointly owned Inventions. If at any time one Party no longer desires to pay for patent costs associated with a patent or patent application that is jointly-owned in accordance with this Section 11.6
(“Discontinuing Party”), the Discontinuing Party will notify the other Party in writing and assign all right, title and interest in such patent or patent application to the other Party to this Agreement, and the Discontinuing
Party will have no further obligation with respect to such patent costs effective the date assignment of the patent or patent application to the other Party becomes effective. 

  

	 	11.7	Disclaimer: Except as otherwise expressly provided in this Article 11, nothing contained in this Agreement shall be construed or interpreted, either expressly or by
implication, estoppel or otherwise, as: (i) a grant, transfer or other conveyance by either Party to the other of any right, title, license or other interest of any kind in any Inventions or other intellectual property, (ii) creating an
obligation on the part of either Party to make any such grant, transfer or other conveyance, or (iii) requiring either Party to participate with the other Party in any cooperative development program or project of any kind or to continue with
any such program or project. 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 27 of 36	 	CONFIDENTIAL

	 	11.8	Rights in Inventions: Except as provided otherwise in Section 11.6 (Jointly Owned Inventions), the Party owning any Invention in accordance with this Article 11 is
entitled to control the drafting, filing, prosecution, maintenance and enforcement of any intellectual property, including patents, covering or claiming the Invention in any territory, including without limitation decisions about the countries in
which to file patent applications or any other forms of intellectual property protections. Costs associated with the intellectual property protection activities described in this Section 11.8 shall be borne by the sole owner. Each Party will
cooperate with the filing Party in the filing and prosecution of patent applications and other forms of intellectual property, at the filing Party’s cost and expense. Such cooperation will include, but not be limited to, furnishing supporting
data and affidavits for the prosecution of patent applications and completing and signing forms needed for the prosecution, assignment and maintenance of patent applications and the other forms of intellectual property. The owner of any Invention in
accordance with this Article 11 has no obligation to account to or obtain consent from the other Party to this Agreement with respect to any activities related to, or any compensation paid to the owner in relation to any Invention, but shall not
grant any rights in any Inventions which would conflict with the licenses granted in Section 11.5. 

  

	 	11.9	Confidentiality of Intellectual Property and Inventions: Inventions, and any intellectual property that covers or claims Inventions, including without limitation patents and
patent applications, shall be deemed to be the Confidential Information of the Party owning such Inventions. The protection of each Party’s Confidential Information is described in Article 10. It shall be the responsibility of the Party
preparing a patent application to use reasonable efforts to limit the disclosure of the other Party’s Confidential Information in any patent application. Should a Party need to disclose the other Party’s Confidential Information to comply
with a patent office’s disclosure requirements the Party must first obtain the written permission of the other Party to use or disclose the other Party’s Confidential Information in the patent application before the application is filed
and for other disclosures made during the prosecution of the patent application and such permission shall not be unreasonable withheld or delayed. NUVELO is entitled to disclose BPS Inventions to sublicensees of the license granted in Section
11.5.1. 

 Article 12, REPRESENTATIONS AND WARRANTIES. 
  

	 	12.1.	Mutual Representations: Each Party hereby represents and warrants to the other Party that: (a) the person executing this Agreement is authorized to execute this
Agreement; (b) this Agreement is legal and valid and the obligations binding upon such Party are enforceable by their terms; and (c) the execution, delivery and performance of this Agreement does not conflict with any agreement, instrument
or understanding, oral or written, to which such Party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

  

					
	NUVELO	 	Page 28 of 36	 	CONFIDENTIAL

	 	12.2	BPS Warranties: BPS represents and warrants that: (a) Drug Product shall be Produced in accordance with cGMP, all Applicable Laws
[        *        ], and has not been adulterated or misbranded by BPS within the meaning of the FD&C Act; (b) to its actual knowledge as of the Effective Date,
BPS has no knowledge of any (i) patents or other intellectual property rights that would be infringed by BPS’ performance of BPS SOPs or (ii) proprietary rights of third parties which would be violated by BPS’ performance of BPS
SOPs; and (c) BPS shall promptly notify NUVELO at such time as it reasonably becomes aware of any infringement or violation discussed in subsection (b) above. BPS represents and warrants that it has obtained (or will obtain prior to
Producing Drug Product), and will remain in compliance with during the Term of this Agreement, all permits, licenses and other authorizations (the “Permits”) which are required under federal, state and local laws, rules and
regulations applicable to the Production of pharmaceutical products generally. BPS shall have no obligation to obtain Permits relating to the sale, marketing, distribution or use of Bulk Drug Substance or Drug Product, or with respect to the
Labeling of Drug Product. BPS makes no representation or warranty with respect to the sale, marketing, distribution or use of the Bulk Drug Substance or as to printed materials specified by NUVELO or its consignee. 

  

	 	12.3	Disclaimer of Warranties: Except for those express representations and warranties set forth in Sections 12.1 and 12.2 and the other Sections of this Agreement, BPS makes no
representations or warranties, written, oral, express or implied, with respect to Drug Product or the Development and Production of Drug Product. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT HEREBY ARE DISCLAIMED BY BPS. NO WARRANTIES OF BPS MAY BE CHANGED BY ANY REPRESENTATIVES OF BPS. NUVELO accepts Drug Product subject to the terms hereof.

  

	 	12.4	NUVELO Warranties: NUVELO warrants that: (a) it has the right to give BPS any information provided by NUVELO hereunder, and BPS is permitted to use such information for
the Production and Development of Drug Product in accordance with the terms and conditions of this Agreement; (b) to its actual knowledge as of the Effective Date, NUVELO has no knowledge of any: (i) patents or other intellectual property
rights that would be infringed by BPS’ Production of Drug Product under this Agreement, but excluding infringement arising out of BPS’ performance of BPS SOPs, or (ii) proprietary rights of third parties which would be violated by
BPS’ performance hereunder, but excluding infringement arising out of BPS’ performance of BPS SOPs; (c) to the actual knowledge as of the Effective Date of the members of NUVELO’s manufacturing group, the members of NUVELO’s
manufacturing group have no knowledge of any: (i) patents or other intellectual property rights that would be infringed by BPS’ performance of BPS SOPs, or (ii) proprietary rights of third parties which would be violated by BPS’
performance of BPS SOPs; (d) NUVELO shall 

 [ * ] Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 29 of 36	 	CONFIDENTIAL

 promptly notify BPS at such time as it reasonably becomes aware of any infringement or violation
discussed in subsection (b) above; and (e) NUVELO’s manufacturing group shall promptly notify BPS at such time as it reasonably becomes aware of any infringement or violation discussed in subsection (c) above. NUVELO further
warrants that, to the best of its knowledge, the Bulk Drug Substance provided to BPS hereunder (1) conforms to the Specifications for BDS; and (2) is not adulterated or misbranded within the meaning of the FD&C Act. 
  

	 	12.5	Disclaimer of Warranties: Except for those express representations and warranties set forth in Section 12.1 and 12.4 and the other Sections of this Agreement, NUVELO
makes no representations or warranties, written, oral, express or implied, with respect to Drug Product, Bulk Drug Substance, NUVELO Supplied Components or the Development and Production of Drug Product. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT HEREBY ARE DISCLAIMED BY NUVELO. NO WARRANTIES OF NUVELO MAY BE CHANGED BY ANY REPRESENTATIVES OF NUVELO. BPS accepts
BDS and NUVELO Supplied Components subject to the terms hereof. 

 Article 13, LIMITATION OF LIABILITY AND WAIVER OF SUBROGATION.

  

	 	13.1	Limitation of Liability: 

  

	 	13.1.1	Each Party’s sole and exclusive remedies for a material breach of this Agreement are those remedies expressly set forth in this Agreement. A Party is entitled to make a claim
for, and obtain as appropriate in the determination of the court or judicial body deciding the claim, direct damages and equitable remedies for a material breach of the terms and conditions of Articles 10 or 11. 

  

	 	13.1.2	BPS Limitation of Liability. Except as expressly provided in Articles 6, 7 or 14 or Sections 3.1.1 or 13.1.1, under no circumstances shall BPS be liable under this Agreement
for loss of use or profits or other collateral, special, consequential or other damages, losses, or expenses, including, but not limited to, the cost of cover, in connection with, or by reason of, the Production and delivery of Drug Product under
this Agreement, whether such claims are founded in tort or contract. All claims by NUVELO for breach or default under this Agreement shall be brought within
[        *        ] after the cause of action accrued, or shall be deemed waived. 

  

	 	13.1.3	NUVELO Limitation of Liability. Except as expressly provided in Sections 2.4 3.4, 4.4, 13.1.1 or Article 14, under no circumstances shall NUVELO be liable under this
Agreement for loss of use or profits or other 

 [ * ] Certain confidential information contained in this document, marked by brackets, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 30 of 36	 	CONFIDENTIAL

 collateral, special, consequential or other damages, losses or expenses, whether such claims are founded
in tort or contract. All claims by BPS for breach or default under this Agreement shall be brought within [        *        ] after the cause of action accrued, or shall
be deemed waived. 
  

	 	13.2	Waiver of Subrogation: All BPS Supplied Components and equipment used by BPS in the Production of Drug Product, other than Capital Equipment and those Components and
equipment that are either paid for by NUVELO or specifically stated in this Agreement to be owned by NUVELO (collectively, the “BPS Property”), shall at all times remain the property of BPS and BPS assumes risk of loss for
BPS Property until, and solely with respect to such BPS Property that is, delivered to NUVELO’s designated carrier as specified under Section 2.9. BPS hereby waives any and all rights of recovery against NUVELO and its Affiliates, and
against any of their respective directors, officers, employees, agents or representatives, for any loss or damage to BPS Property to the extent the loss or damage is covered or could be covered by insurance (whether or not such insurance is
described in this Agreement). NUVELO assumes all risk of loss for all NUVELO Supplied Components, all Bulk Drug Substance supplied by NUVELO, and all Drug Product (collectively, the “NUVELO Property”), except as expressly
stated in Article 6. NUVELO hereby waives any and all rights of recovery against BPS and its Affiliates, and against any of their respective directors, governors, members, officers, employees, agents or representatives, for any loss or damage to the
NUVELO Property to the extent the loss or damage is covered or could be covered by insurance (whether or not such insurance is described in this Agreement), except as expressly stated in Article 6. 

 Article 14, INDEMNIFICATION. 
  

	 	14.1	NUVELO Indemnification: NUVELO shall indemnify, defend and hold harmless BPS and its Affiliates, and any of their respective directors, officers, employees, contractors
authorized by Section 5.2 and agents (collectively, the “BPS Indemnified Parties”) from and against any and all liabilities, penalties, claims, judgments, demands, actions, disbursements of any kind and nature, suits, losses,
damages, costs and expenses (including, without limitation, reasonable attorney’s fees) resulting from or arising out of property damage or personal injury (including without limitation death) of third parties (collectively, the
“Claims”), including Claims [        *        ], that result from or arise out of: (a) the storage, promotion, labeling, marketing,
distribution, use or sale of Bulk Drug Substance or Drug Product, (b) from NUVELO’s negligence or willful misconduct, (c) NUVELO’s breach of its obligations under this Agreement, (d) any claim that the Production of Drug
Product by BPS violates the patent, trademark, copyright or other proprietary rights of any third party, or (e) the inherent clinical and pharmacological properties of the Bulk Drug Substance or Drug Product; except in each case of
(a) through (e) above, to the extent BPS is obligated to indemnify, defend and hold harmless NUVELO with respect to such Claims under Section 14.2 and/or 14.3. BPS Indemnitees shall fully cooperate 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 31 of 36	 	CONFIDENTIAL

 with NUVELO in the defense or settlement of any Claims under this Section 14.1; provided, however,
that no BPS Indemnitee shall be required to admit fault or responsibility in connection with any settlement. BPS Indemnitees shall have the right to select and to obtain representation by separate legal counsel at its own expense. 
  

	 	14.2	BPS Indemnification: Subject to Section 14.3, BPS shall indemnify, defend and hold harmless NUVELO and its Affiliates and any of their respective directors, officers,
employees, subcontractors and agents (collectively, the “NUVELO Indemnified Parties”) from and against any and all Claims to the extent that such Claims result from or arise out of: (a) BPS’ negligence or
willful misconduct, (b) BPS’ breach of its warranties or obligations set forth in this Agreement, or (c) any claim that BPS’ use of BPS’ intellectual property in the Production of Drug Product violates the patent, trademark,
copyright or other proprietary rights of any third party. NUVELO Indemnitees shall fully cooperate with BPS in the defense or settlement of any Claims under this Section 14.2; provided, however, that no NUVELO Indemnitee shall be required to
admit fault or responsibility in connection with any settlement. NUVELO Indemnitees shall have the right to select and to obtain representation by separate legal counsel at its own expense. 

  

	 	14.3	Joint Liability: In the event that an obligation to indemnify arises under both Sections 14.1 and 14.2, liability will be
[        *        ] in accordance with [        *        ]; provided, however, that
[        *        ]. 

  

	 	14.4	Indemnitee Obligations: A Party (the “Indemnitee”) which intends to claim indemnification or defense under this Article 14 shall notify the other Party (the
“Indemnitor”) in writing of any Claim in respect of which the Indemnitee or any of its Affiliates, or any of their respective directors, officers, employees, subcontractors, or agents, intend to claim such indemnification no later
than [        *        ] days after Indemnitee received notice of such Claim; provided, however, that failure to provide such notice within
[        *        ] days shall not relieve the Indemnitor of any of its obligations hereunder unless and to the extent the Indemnitor’s ability to indemnify or
defend against the Claim is prejudiced by such failure. The Indemnitee shall permit, and shall cause its Affiliates, and their respective directors, officers, employees, subcontractors and agents to permit, the Indemnitor, at its discretion, to
settle any such Claim and have complete control of such defense or settlement by the Indemnitor. Notwithstanding the foregoing, the Indemnitor shall not enter into any settlement that would adversely affect the Indemnitee’s rights hereunder, or
impose any obligations on the Indemnitee in addition to those set forth herein, in order for it to exercise such rights, without Indemnitee’s prior written consent, which shall not be unreasonably withheld or delayed. No such Claim shall be
settled by an Indemnitee without the prior written consent of the Indemnitor, which shall not be unreasonably withheld or delayed. The Indemnitee, its Affiliates, and their respective directors, officers, 

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 32 of 36	 	CONFIDENTIAL

 employees, subcontractors and agents shall fully cooperate with the Indemnitor and its legal
representatives in the investigation and defense of any such Claim covered by the indemnification obligations of this Article 14. The Indemnitee shall have the right, but not the obligation, to be represented in such defense by counsel of its own
selection, at its own cost and expense. 
 Article 15, INSURANCE. 
  

	 	15.1	Insurance: NUVELO shall maintain, during the Term of this Agreement and for a period
[        *        ] beyond the expiration date of Finally Released Drug Product, Commercial General Liability Insurance, including without limitation, Product Liability
and Contractual Liability coverage (the “NUVELO Insurance”). The NUVELO Insurance shall cover amounts not less than [        *        ]
combined single limit and shall be with an insurance carrier with an [        *        ]. BPS shall be named as an additional insured on the NUVELO Insurance and
NUVELO promptly shall deliver a certificate of NUVELO Insurance and endorsement of additional insured to BPS evidencing such coverage. If NUVELO fails to furnish such certificates or endorsements, or if at any time during the Term of this Agreement
BPS is notified of the cancellation, termination or lapse of the NUVELO Insurance, and NUVELO fails to rectify the same within [        *        ] days after notice from
BPS, in addition to all other remedies available to BPS hereunder, BPS, at its option, may obtain the NUVELO Insurance and NUVELO promptly shall reimburse BPS for the cost of the same. Any deductible and/or self- insurance retention shall be the
sole responsibility of NUVELO. 

  

	 	15.2	BPS Insurance: BPS is, and shall during the Term of this Agreement remain, self-insured for the type of liability that could arise under Article 14 (Indemnification Article)
of this Agreement. BPS is, and shall during the Term of this Agreement remain, self-insured up to no less than [        *        ]. 

  

	 	15.3	No Limitation: In no event will the liability of either Party be limited to that which is recoverable by insurance. 

 Article 16, GENERAL PROVISIONS. 
  

	 	16.1	Notices: All notices hereunder shall be delivered by facsimile (confirmed by overnight delivery), or by overnight delivery with a reputable overnight delivery service, to the
following address of the respective Parties: 

  

			
	 If to NUVELO:
	 	Nuvelo, Inc.
		 	201 Industrial Road, Suite 310
		 	San Carlos, CA 94070
		 	Attn: Legal Department
		
		 	Telephone: (650)517-8000
		 	Facsimile: (650) 517-8001

 [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 
  

					
	NUVELO	 	Page 33 of 36	 	CONFIDENTIAL

			
	 If to BPS:
	 	Baxter Pharmaceutical Solutions LLC
		 	927 South Curry Pike
		 	Bloomington, IN 47403
		 	Attn: Contract Management
		
		 	Telephone: (812) 333-0887
		 	Facsimile: (812) 332-3079

 Notices shall be effective on the date of transmission if sent by facsimile, and on the date of
delivery to the overnight delivery service if sent by overnight delivery. A Party may change its address listed above by notice to the other Party given in accordance with this Section 16.1. 
  

	 	16.2	Entire Agreement; Amendment: The Parties hereto acknowledge that this Agreement, the Plans and the Quality Agreement set forth the entire agreement and understanding of the
Parties with respect to the subject matter of this Agreement and supersedes all prior written or oral agreements or understandings with respect to the subject matter hereof, including without limitation, the Confidentiality Agreement signed by the
Parties on May 27, 2005. No modification of any of the terms of this Agreement or any of the Plans or any amendments of the preceding, shall be deemed to be valid unless in writing and signed by a duly authorized representative of both Parties
hereto. No course of dealing or usage of trade shall be used to modify the terms and conditions herein. 

  

	 	16.3	Waiver: None of the provisions of this Agreement shall be considered waived by any Party hereto unless such waiver is agreed to, in writing, by authorized representatives of
both Parties. The failure of a Party to insist upon strict conformance to any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any Party hereto.

  

	 	16.4	Assignment: This Agreement shall be binding upon and inure to the benefit of the successors or permitted assigns of each of the Parties. This Agreement shall not be assigned
or transferred, in whole or in part, by either Party without the prior written consent of the other Party, except that no consent shall be required from the other Party in the case of a merger, consolidation or sale of all of the assets of the Party
seeking such assignment or transfer that relate to the business covered by this Agreement and the resulting entity assumes all of the rights and obligations under this Agreement. Either Party may, without such consent, assign this Agreement to an
Affiliate that is being assigned all or substantially all of the assets of the assigning Party that relate to the business covered by this Agreement, if and only if such Affiliate assumes all obligations of the assigning Party under this Agreement.
No assignment shall relieve any Party of responsibility for the 

  

					
	NUVELO	 	Page 34 of 36	 	CONFIDENTIAL

 performance of its obligations hereunder. Any transfer or assignment that is not consistent with the
terms and conditions of this Section 16.4 is null and void. 
  

	 	16.5	Taxes: NUVELO shall pay all national, state, and municipal sales taxes assessed upon or levied against the sale of Drug Product to NUVELO pursuant to this Agreement or the
sale or distribution of Drug Product by NUVELO (or at NUVELO’s sole expense, defend against the imposition of such taxes). BPS shall notify NUVELO of any sales taxes that any governmental authority is seeking to collect from BPS, and NUVELO may
assume the defense thereof in BPS’ name, if necessary, and BPS shall fully cooperate in such defense to the extent of the capacity of BPS, at NUVELO’s expense. BPS shall pay all national, state, municipal or other taxes, other than sales
taxes, resulting from the Production of and sale by BPS of the Drug Product to NUVELO under this Agreement, including but not limited to, gross income, adjusted gross income, supplemental net income, gross receipts, property taxes, excess profit
taxes, or other similar taxes. 

  

	 	16.6	Independent Contractor: BPS is and shall act as an independent contractor for NUVELO in providing the services required hereunder and a Party hereto shall not be considered
an agent or partner of, or joint venturer with, the other Party. Unless otherwise expressly provided to the contrary in this Agreement, BPS shall furnish all expertise, labor, supervision, machinery and equipment necessary for performance hereunder
and shall obtain and maintain all building and other permits and licenses required by public authorities. 

  

	 	16.7	Governing Law: In any action brought regarding the validity, construction and enforcement of this Agreement, it shall be governed in all respects by the laws of the State of
Delaware, without regard to the principles of conflicts of laws. The courts of the State of Delaware shall have personal jurisdiction over the Parties hereto in all matters arising hereunder, and venue for such suit will be in a state or federal
court located in the state of Delaware. 

  

	 	16.8	Attorney’s Fees: The successful Party in any litigation or other dispute resolution proceeding to enforce the terms and conditions of this Agreement may be awarded, in
the discretion of the judicial body adjudicating the dispute, reasonable attorney’s fees and related costs involved in connection with such litigation or dispute resolution proceeding. 

  

	 	16.9	Severability: In the event that any term or provision of this Agreement shall violate any applicable statute, ordinance, or rule of law in any jurisdiction in which it is
used, or otherwise be unenforceable, such provision shall be ineffective to the extent of such violation without invalidating any other provision hereof. 

  

	 	16.10	Headings, Interpretation, Counterparts: The headings used in this Agreement are for convenience only and are not intended to limit or expand on the meaning of the language
contained in the particular article or section. This Agreement may ineffective to the extent of such violation without invalidating any other provision hereof. 

  

					
	NUVELO	 	Page 35 of 36	 	CONFIDENTIAL

	 	16.10	Headings, Interpretation, Counterparts: The headings used in this Agreement are for convenience only and are not intended to limit or expand on the meaning of the language
contained in the particular article or section. This Agreement may be executed in two (2) or more counterparts, including facsimile counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

 IN WITNESS WHEREOF, this Drug Product Development and Clinical Supply Agreement takes effect on the Effective Date
when it has been executed by the duly-authorized representatives of the Parties. 
  

							
	 NUVELO, INC.
	 	BAXTER PHARMACEUTICAL SOLUTIONS LLC
				
	 By:
	  	 /s/ Michael D. Levy
  
	 	By:	 	 /s/ Joel A. Tune
  

	 Name:
	  	Michael Levy, M.D.	 	Name:	 	Joel A. Tune
	 Title:
	  	SR. Vice President	 	Title:	 	Vice President
	 Date:
	  	5 May 2006	 	By:	 	May 2, 2006

 

 
  

					
	NUVELO	 	Page 36 of 36	 	CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]